 
A RANDOMIZED, DOUBLE -BLIND, AC TIVE - AND PLACEBO -CONTROLLED, 
6-WAY CROSSOVER STUDY TO EVALUATE  THE ABUSE POTENTIAL OF 
ORALLY ADMINISTERED GABAPENTIN ENACARBIL IMMEDIATE RELEASE 
CAPSULES  TAKEN ALONE AND IN COMBINATION  WITH OXYCODONE  IN 
HEALTHY, NONDEPENDENT, RECREATIONAL OPI[INVESTIGATOR_483228]:  AR26.3031.[ADDRESS_621021] Number:  ABO -P4-[ADDRESS_621022]:  Gabapentin Enacarbil Immediate Release 
Capsules  
Phase of Development:  Not applicable  
Sponsor:  Arbor Pharmaceuticals, LLC  
[ADDRESS_621023] icable federal and local regulations . 
Protocol Version  Date  
2.0 (Amendment 01)  August 1 3, 2021  
 
 
 
 
CONFIDENTIALITY STATEMENT  
The information provided in this document is strictly confidential and is available for review to investigator(s) 
and to the  appropriate Independent Ethics Committee  (IEC) or Institutional Review Board (IRB). It may not be 
used, divulged, published or otherwise disclos ed without the written authoriza tion from Altasciences  or the 
sponsor.  
Protocol No: AR26.3031.[ADDRESS_621024] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 2 of 84 
PROTOCOL AMENDMENT 01 – SUMMARY OF CHANGES  
Description of Change Made  Section/Location  Rationale  
Modified the primary objectives 
to remove the evaluation of 
abuse potential for single oral 
doses of GE -IR taken alone . • Synopsis (Primary 
Objectives)  
• Section 2 (Study 
Objectives and Endpoints)  Added as per FDA 
recommendation.  
Added appropriateness of 
including High VAS as a key 
secondary endpoint  Section 8.2 (Appropriateness 
of Measures)  Added High VAS for 
completeness.  
Added “in addition to the optio n 
“RANDOM SUBJECT;”  Section [IP_ADDRESS] (Primary 
Analysis)  Added clarification, as per 
FDA recommendation.  
Added sentence s clarifying that 
Hypotheses 3 and 4 will be 
removed. Removed Hypotheses 
3 and 4, and any references to 
them for  the primary endpoint.  Section [IP_ADDRESS] (Primary 
Analysis), Test Hypotheses 
for Primary Endpoint, Drug 
Liking VAS E max) Added as per FDA 
recommendation: the 
primary objective is 
pertaining to the combination 
drug of GE -IR and OXY20 
rather than GE -IR alone.  
Removed Hypotheses 3 and 4, 
and any references to them for 
key secondary endpoints  Section [IP_ADDRESS] (Primary 
Analysis), Test Hypotheses 
for Key Secondary 
Endpoints  Added as per FDA 
recommendation: the 
primary objective is 
pertaining to the combination 
drug of GE -IR and OXY20 
rather than GE -IR alone.  
Removed Hypotheses 3 and 4, 
and any references to them for 
non-key secondary endpoints  Section [IP_ADDRESS] (Primary 
Analysis), Test Hypotheses 
for Non -Key Secondary 
Endpoints  Added as per FDA 
recommendation: the 
primary obj ective is 
pertaining to the combination 
drug of GE -IR and OXY20 
rather than GE -IR alone.  
Removed reference for “Chen 
L. Statistical Considerations on 
Pharmacodynamic Assessment 
of Human Abuse Potential 
Studies. CCALC/CSS, October 
11, 2018”, as it contains  
information regarding the alpha 
level for [ADDRESS_621025] been 
removed.  Section 9 (References)  Reference no longer needed.  
 
Protocol No: AR26.3031.[ADDRESS_621026] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 3 of 84 
TABLE OF CONTENTS  
PROTOCOL AMENDMENT 01 – SUMMARY OF CHANGES  ................................ ................................ ...........  [ADDRESS_621027] OF IN -TEXT TABLES  ................................ ................................ ................................ ................................ ..... 7 
STUDY SYNOPSIS  ................................ ................................ ................................ ................................ .....................  8 
INVESTIGATOR AND STUDY ADMINISTRATIVE STRUCTURE  ................................ ................................  15 
1. INTRODUCTION  ................................ ................................ ................................ ................................ ..............  17 
1.1. Background  ................................ ................................ ................................ ................................ ...................  17 
1.2. Study Rationale  ................................ ................................ ................................ ................................ .............  17 
1.3. Rationale for Dose Selection  ................................ ................................ ................................ .........................  20 
1.4. Risk/Benefit Assessment  ................................ ................................ ................................ ...............................  [ADDRESS_621028] Treatment Administration ................................ ................................ ................................ ..... 32 
4.6. Lifestyle and/or Dietary Requirements  ................................ ................................ ................................ .........  [ADDRESS_621029] Management  ................................ ................................ ................................ ............  34 
5.2.1. Packaging, Labeling and Dispensing  ................................ ................................ ................................ ..... 34 
5.2.2.  Storage and Handling  ................................ ................................ ................................ .............................  34 
Protocol No: AR26.3031.[ADDRESS_621030] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 4 of 84 
5.2.3.  Method of Assigning Subjects to Treatment Groups  ................................ ................................ .............  35 
5.2.4.  Blinding  ................................ ................................ ................................ ................................ ..................  36 
5.2.5.  Study Drug Accountability ................................ ................................ ................................ .....................  36 
5.3. Study Treatment Administration, Meals and Fluids  ................................ ................................ ......................  37 
5.3.1.  Treatme nt Compliance  ................................ ................................ ................................ ...........................  37 
5.4. Other Protocol Restrictions  ................................ ................................ ................................ ...........................  37 
6. STUDY PROCEDURES  ................................ ................................ ................................ ................................ .... 37 
6.1. Safety Assessments  ................................ ................................ ................................ ................................ ....... 38 
6.1.1.  Medical History  ................................ ................................ ................................ ................................ ...... 38 
6.1.2.  Recreat ional Alcohol/Drug Use  ................................ ................................ ................................ .............  38 
6.1.3.  Physical Examination  ................................ ................................ ................................ .............................  38 
6.1.4.  Vital Signs  ................................ ................................ ................................ ................................ ..............  39 
6.1.5.  12-Lead Electrocardiogram  ................................ ................................ ................................ ....................  40 
6.1.6.  Laboratory Evaluations  ................................ ................................ ................................ ..........................  40 
6.1.7.  Columbia Suicide Severity Rating Scale (C -SSRS)  ................................ ................................ ...............  40 
6.1.8.  Assessment of Respi[INVESTIGATOR_47703]  ................................ ................................ ................................ .. 40 
6.1.9.  Rescue Therapy  ................................ ................................ ................................ ................................ ...... 41 
6.2. Blood Volume Collected  ................................ ................................ ................................ ...............................  41 
6.3. Pharmacokinetic Assessments  ................................ ................................ ................................ .......................  41 
6.3.1.  Pharmacokinetic Sample Proc essing, Storage and Shippi[INVESTIGATOR_007]  ................................ ................................ .. 42 
6.4. Pharmacodynamic Assessments  ................................ ................................ ................................ ....................  43 
6.4.1.  Subjective Effects ................................ ................................ ................................ ................................ ... 43 
6.4.2.  Modified Observer’s Assessment of Alertness/Sedation (MOAA/S)  ................................ ....................  45 
7. ADVERSE EVENTS DOCUMENTATION  ................................ ................................ ................................ .... 45 
7.1. Definitions  ................................ ................................ ................................ ................................ .....................  45 
7.2. Severity Assessment  ................................ ................................ ................................ ................................ ...... 46 
7.3. Causality Assessment  ................................ ................................ ................................ ................................ .... 47 
7.4. Adverse Event Monitoring  ................................ ................................ ................................ ............................  47 
7.5. Reporting of Pregnancy  ................................ ................................ ................................ ................................ . 48 
7.6. Serious Adverse Event Reporting  ................................ ................................ ................................ .................  48 
8. DATA ANALYSIS AND STATISTICAL METHODS  ................................ ................................ ...................  49 
8.1. Analysis Populations  ................................ ................................ ................................ ................................ ..... 49 
8.2. Appropriateness of Measures  ................................ ................................ ................................ ........................  50 
8.3. Missing Values  ................................ ................................ ................................ ................................ ..............  50 
8.4. Demographic Data and Other Baseline Characteristics  ................................ ................................ .................  51 
8.5. Pharmacodynamics  ................................ ................................ ................................ ................................ ........  52 
Protocol No: AR26.3031.[ADDRESS_621031] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 5 of 84 
8.5.1.  Pharmacodynamic Endpoints  ................................ ................................ ................................ .................  52 
8.5.2.  Pharmacodynamic Statistical Methodology  ................................ ................................ ...........................  52 
8.6. Pharmacokinetics  ................................ ................................ ................................ ................................ ..........  58 
8.6.1.  Measurements Below the Lower Limit of Quantitation  ................................ ................................ .........  58 
8.6.2.  Actual Time  ................................ ................................ ................................ ................................ ............  58 
8.6.3.  Noncompartmental Analysis (NCA)  ................................ ................................ ................................ ...... 58 
8.6.4.  Pharmacokinetic Statistical Methodology  ................................ ................................ ..............................  59 
8.7. Safety ................................ ................................ ................................ ................................ .............................  60 
8.7.1.  Safety Endpoints  ................................ ................................ ................................ ................................ .... 60 
8.7.2.  Safety Analysis ................................ ................................ ................................ ................................ ....... 60 
8.8. Planned Interim Analyses  ................................ ................................ ................................ ..............................  61 
8.9. Determination of Sample Size  ................................ ................................ ................................ .......................  61 
9. REFERENCES  ................................ ................................ ................................ ................................ ...................  63 
10. APPENDIX 1: ETHICS  ................................ ................................ ................................ ................................ ..... [ADDRESS_621032] Confidentiality  ................................ ................................ ................................ ................................ .. 66 
11. APPENDIX 2: DATA COLLECTION, RETENTION, AND MONITORING  ................................ ............  [ADDRESS_621033] Retention  ................................ ................................ ................................ ................................ ...........  68 
11.5.  Monitoring of the Study  ................................ ................................ ................................ ................................  68 
12. APPENDIX 3: ADMINISTRATIVE PRO CEDURES  ................................ ................................ ....................  69 
12.1.  Liabilities  ................................ ................................ ................................ ................................ .......................  69 
12.2.  Adherence to Protocol  ................................ ................................ ................................ ................................ ... 69 
12.3.  Statement of Investigator  ................................ ................................ ................................ ...............................  69 
12.4.  Delegation of Investigator Duties  ................................ ................................ ................................ ..................  69 
12.5.  Premature Termination or Suspension of a Study  ................................ ................................ .........................  69 
13. APPENDIX 4: PROTOCOL REVIEW AND APPROVALS  ................................ ................................ .........  70 
14. APPENDIX 5: LIST OF ABBREVIATIONS  ................................ ................................ ................................ .. 72 
15. APPENDIX 6: CLINICAL LABORATORY EVALUATIONS  ................................ ................................ ..... 75 
16. APPENDIX 7: COLUMBIA -SUICIDE SEVERITY RATING SCALE (C -SSRS) –
BASELINE/SCREENING VERSION  ................................ ................................ ................................ .....................  76 
17. APPENDIX 8: COLUMBIA -SUICIDE SEVERITY RATING SCALE (C -SSRS) –SINCE LAST VISIT 
VERSION  ................................ ................................ ................................ ................................ ................................ ... 79 
Protocol No: AR26.3031.[ADDRESS_621034] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 6 of 84 
18. APPENDIX 9: ADDICTION RESEARCH CENTER INVENTORY (ARCI) MORPHINE -
BENZEDRINE GROUP (MBG) SCALE  ................................ ................................ ................................ ................  82 
19. APPENDIX 10: ADDICTION RESEARCH CENTER INVENTORY (ARCI) PENTOBARBITAL -
CHLORPROMAZINE -ALCOHOL GROUP (PCAG) SCALE  ................................ ................................ ............  83 
20. APPENDIX 11: CLINICAL OPI[INVESTIGATOR_483229] (COWS)  ................................ ..................  84 
 
Protocol No: AR26.3031.[ADDRESS_621035] Number: ABO -P4-[ADDRESS_621036] OF IN-TEXT TABLES  
Table 1. Schedule of Activities  ................................ ................................ ................................ ..... 11 
Table 2  Sample Qualification Phase Sequences  ................................ ................................ ..........  35 
Table 3  Sample Treatment Phase Sequences  ................................ ................................ ..............  36 
Table 4. Pharmacokinetic Blood Sampling Schedule (Gabapentin and Oxycodone)  ..................  42 
Table 5. Visual Analog Scale (VAS) Descriptions  ................................ ................................ ....... 44 
Table 6. Adverse Event Relationship to Study Drug  ................................ ................................ .... 47 
Table 7. Pharmacodynamic Endpoints  ................................ ................................ .........................  52 
Table 8. Pharmacokinetic Parameters  ................................ ................................ ...........................  59 
Protocol No: AR26.3031.[ADDRESS_621037] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 8 of 84 
STUDY SYNOPSIS  
Name [CONTACT_44713]/Company:  Arbor Pharmaceuticals, LLC  
Name [CONTACT_35215]:  Gabapentin enacarbil immediate release capsules (GE -IR) 
Title of Study:  A Randomized, Double -Blind, Active - and Placebo -Controlled, 6-Way 
Crossover Study to Evaluate  the Abuse Potential of Orally Administered 
Gabapentin Enacarbil Immediate Release Capsules Taken Alone and in 
Combination  with Oxycodone  in Healthy, Nondependent,  Recreational Opi[INVESTIGATOR_483230]:  Not applicable  
Objectives:  Primary Objective s: 
To evaluate the abuse potential of single oral doses of GE -IR taken in 
combination  with an opi[INVESTIGATOR_483231] ( oxycodone) in healthy, 
nondependent, recreational opi[INVESTIGATOR_483232]:  
To evaluate the pharmacokinetics (PK) of gabapentin from GE-IR when 
administered alone or in combination  with oxycodone in healthy  nondependent,  
recreational opi[INVESTIGATOR_483233] -IR 
taken alone or in combination  with oxycodone, compared  to placebo and 
oxycodone  alone , in healthy  nondependent , recreational opi[INVESTIGATOR_483234]:  Pharmacodynamic (PD)  Endpoints : 
The primary endpoint of this study will be maximum (peak) effect (E max) over 
24 hours for Drug Liking (“at this moment”), assessed on a bipolar (0 to 
100 points) visual analog scale (VAS).  
Key Secondary PD endpoints will be:  
• Overall Drug Liking VAS (E max) 
• Take  Drug Again VAS (E max) 
• High VAS (E max) 
Non-Key Secondary PD endpoints will be:  
Balance of Effects  
• Drug Liking VAS (minimum effect [E min], time of maximum effect 
[TE max], time of minimum effect [TE min], and time-averaged area und er 
the effect -time curve [ TA_AUE ]) 
Positive Effects  
• Good Effects VAS (E max, TE max, and TA_AUE)  
• High VAS (E max, TE max, and TA_AUE)  
Negative Effects  
• Bad Effects VAS (E max, TE max, and TA_AUE)  
Protocol No: AR26.3031.[ADDRESS_621038] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 9 of 84 
Other Subjective Effects  
• Any Effects VAS (E max, TE max, and TA_AUE)  
• Feeling  Drunk VAS (E max, TE max, and TA_AUE)  
• Drowsiness/Alertness VAS (E min, TE min, and area over the effect -time 
curve [TA_AUE])  
• Relaxation/Agitation (E min, TE min, and TA_AUE)  
• Addiction Research Center Inventory (ARCI) Morphine -Benzedrine 
Group (MBG) Scale (E max, TE max, and TA_AUE)  
• ARCI Pentobarbital –Chlorpromazine –Alcohol Group (PCAG) Scale 
(Emax, TE max, and TA_AUE)  
Observer Assessments  
• Modified Observer’s Assessment of Alertness/Sedation (MOAA/S; 
Emin, CFB min, and TA_AUE)  
Pharmacokinetic  Endpoints : 
Pharmacok inetic parameters of gabapentin include maximum observed 
concentration (C max), time of occurrence of C max (Tmax), area under the curve 
from time [ADDRESS_621039] measureable observed concentration (AUC 0-t), and area 
under the curve from time 0 to infinity (AU C0-inf). 
Safety  Endpoints : 
Endpoints will include a summary of the incidence of adverse events ( AEs), 
serious adverse events (SAEs), as well as descriptive summary and statistics of 
the safety parameters . 
Safety parameters will include clinical laboratory values, vital signs 
(i.e., systolic and diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], oral 
temperature, oxygen saturation [SpO 2]), continuous SpO 2 monitoring, 
continuous End Tidal CO 2, electrocardiograms (ECGs), Columbia Suicide 
Severi ty Rating Scale (C -SSRS), and physical examination findings.  
Study Product , 
Dose s, and Mode of 
Administration 
(proposed):  Gabapentin Enacarbil Immediate Release (GE -IR) Capsules  
Manufacturer:  Arbor Pharmaceuticals, LLC  
Mode of administration: Doses of GE -IR 200 mg and 450 mg will be 
administered orally according to the randomization schedule during the 
treatment phase.  
GE-IR Placebo, 
Dose, and Mode of 
Administration:  Placebo -to-match GE -IR capsules  
Manufacturer:  Arbor Pharmaceuticals, LLC  
Mode of administration: Single doses of placebo -to-match GE -IR will be 
administered orally according to the randomization schedule during the 
treatment phase.  
Active Control, Dose, 
and Mode of 
Administration:  Oxycodone 10 mg immediate -release (IR) tablets  
Dose:  Over -encapsulated o xycodone 20 mg; administered as 2 × 10 mg tablets  
Mode of administration: Single doses of oxycodone 20 mg will be administered 
orally alone or in combination with GE-IR, according to the randomization 
Protocol No: AR26.3031.[ADDRESS_621040] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 10 of 84 
schedule, during the qualification and treatment phases , respectively . 
Oxycodone Placebo, 
Dose, and Mode of 
Admin istration:  Placebo -to-match oxycodone  
Over -encapsulated placebo tablets to match oxycodone  IR tablets  
Mode of administration: Single doses of placebo -to-match oxycodone tablets 
will be administered orally alone or in combination with GE-IR, according to 
the randomization schedule , during the qualifi cation and treatment phase s, 
respectively . 
Naloxone, Dose and 
Mode of 
Administration:  Naloxone HCl solution for intravenous (i.v.) injection , 0.4 mg/mL  
Mode of administration: Naloxone HCl will be administered as i.v. bolus 
injections in single ascending doses of 0.2 mg (Step 1) and 0.6 mg (Step 2) 
during the qualification phase . 
Study Design:  This study will be a randomized, double -blind, active - and placebo -controlled, 
6-way crossover study to evaluate  the abuse potential , PK, safety and 
tolerability  of GE-IR co-administered with oxycodone  relative to  GE-IR alone,  
oxycodone , and placebo, in nondependent, recreational opi[INVESTIGATOR_45157].  
This study will consist of 4 phases: screening , qualification, treatment, and 
follow -up. 
Duration of 
Treatment and 
Subject 
Confinement:  Duration of clinical trial (per subject):  
Screening: Day -30 to Day -2 (up to 28 days)  
Treatment period (qualification, treatment, and follow -up phases) : Subjects will 
be confined to the clinical site from Day -[ADDRESS_621041] dose of study drug  (Day  23 ±2 days) . 
Total study duration: up to 59 days (including screening)  
Study Population:  Healthy , male and female nondependent , recreational opi[INVESTIGATOR_45157] , aged 18 to 
55 years . 
Planned Number of 
Subjects:  Approximately [ADDRESS_621042] 54 subjects  complete the treatment phase of the study . 
Bioanalysis:  Gabapentin  and oxycodone  plasma concentrations will be measured by 
[CONTACT_483279] s. 
Pharmacokinetic 
Analysis:  Pharmacokinetic analyses will be performed by [CONTACT_105] -compartmental analysis 
(NCA) and  Cmax, Tmax, AUC 0-t, and AUC 0-inf will be estimated for gabapentin  
and oxycodone . 
The PK analys is will be further detailed in the  statistical analysis plan ( SAP). 
Statistical Analysis : The PD and PK statistical analyse s are discussed in section s 8.5 and 8.6, 
respectively,  and will be fully detailed in the  SAP.  
Safety Analysis:  The safety analysis is discussed in section 8.7 and will be fully detailed in the 
SAP.  
 
Protocol No: Protocol No: AR26.3031.[ADDRESS_621043] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 11 of 84 
Table 1. Schedule of Activities  
 Screening  Qualification 
Phasea Treatment Phase  Early 
Termination 
(ET)/  
Follow -Up 
Visit b 
Day -30 to -2 -1 1 2 3 -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 23±[ADDRESS_621044] Review                          
Informe d consentc X                        
Demographics  X                        
Inclusion/exclusi on 
criteria review  X X    Xd                   
Medical histor y X                        
Medication & 
recreational drug 
use history  X X    X                   
C-SSRSe X X   X
f Xf                 X X 
Study restriction s 
review   X   X
f Xf                 X X 
Safety                          
Physical 
examination  X Xg   Xf, g Xf,g                 Xg Xg 
Height, weight & 
body mass index 
(BMI)  X                        
Pregnancy testh X X    Xf                 X X 
Urine drug and 
alcohol screen  X X    Xf                   
COVID -19 testv  X    Xf                   
Clinical laborato ry 
evaluations  X X   X
f X                 X X 
Follicle stimulat ing 
hormone (FSH)i X                        
Serologyj X                        
Protocol No: Protocol No: AR26.3031.[ADDRESS_621045] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 12 of 84 
 Screening  Qualification 
Phasea Treatment Phase  Early 
Termination 
(ET)/  
Follow -Up 
Visit b 
Day -30 to -2 -1 1 2 3 -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 23±2 
Vital signsk X X X X X Xf X X  X X  X X  X X  X X  X X X 
12-lead ECG  X X    Xf                 X X 
Continuous 
respi[INVESTIGATOR_483235]   X X   X   X   X   X   X   X   
Continuous pul se 
oximetryl   X X   X   X   X   X   X   X   
Continuous and 
Spot End Tidal 
CO 2l   X X   X   X   X   X   X   X   
Concomitant 
medic ationsm X X X X X X X X X X X X X X X X X X X X X X X X 
Adverse eve nts 
(AEs)n X X X X X X X X X X X X X X X X X X X X X X X X 
Pharmaco -
dynamics (PD)                          
Training/pract iceo  X    X                   
Subjective 
measuresp   X X X  X X  X X  X X  X X  X X  X X  
MOAA/ Sq   X X   X   X   X   X   X   X   
Pharmacokinetics 
(PK)                          
PK blood sampl esr       X X  X X  X X  X X  X X  X X  
Study 
Administrat ion                         
Admissionf  X    Xf                   
Naloxone 
challenge   X                       
COWS   X                       
Randomizations  X    X                   
Protocol No: Protocol No: AR26.3031.[ADDRESS_621046] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 13 of 84 
 Screening  Qualification 
Phasea Treatment Phase  Early 
Termination 
(ET)/  
Follow -Up 
Visit b 
Day -30 to -2 -1 1 2 3 -1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 23±2 
Study treatment 
administration    X
t X
t   Xu   Xu   X
u   Xu   Xu   Xu   
Discharge      X
f                  X  
C-SSRS= Columb ia Suicide Severity Rating Scale, ECG= electrocardiogram,  GE-IR = Gabapentin Enacarbil Immediate Release, MOAA/S= Modified Observer’s As sessment of 
Alertness/Sedation , COWS= Clinical Opi[INVESTIGATOR_483236], procedures should be ca rried out in the following order, with the following windows: (1) vital signs , ECG  and spot EtCO 2 (±15 minutes), (2) VAS/PD 
(±15  minutes), (3) PK blood sampling (±5 minutes), (5) MOAA/S to be done at any time around the other procedures (±30 minutes).  
 
a Includes naloxone challenge and qualification (oxycodone versus placebo).  
b Early termination/f ollow -up visit can be performed in a window of ±[ADDRESS_621047]’s inclusion (prior to naloxone challenge on Day -1) 
d Review of qualification criteria (section 4.3). 
e Baseline/screening version of C-SSRS evaluation at screening visit. Since last vi sit version of C-SSRS evaluation at all other visits . 
f Subjects should remain housed at the clinical research unit (CRU) from Day -1 of the qualification phase through Day 17 of the treatment phase.  Only if subjects are discharged 
between the qualificatio n and treatment phases, the noted discharge procedures will be performed on Day 3 of the qualification phase and noted admiss ion procedures will be 
performed again on Day -1 (treatment phase). If subjects remain housed at the CRU the noted procedures are N OT required. Time between discharge from the qualification phase 
and admission for the treatment phase cannot exceed [ADDRESS_621048] at all other visits.  
i Postmenopausal women only.  
j Serology screening as described in  APPENDIX 6APPENDIX 6 . 
k Blood pressure, pulse rate, oxygen saturation (SpO 2) and respi[INVESTIGATOR_697].  Measured at screening; each admission to the qualification phase and treatment phase; within 1 hour 
prior to and approximately 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours following each study drug administration. Oral te mperature req uired at screening and at check -in (Day -1) 
for the qualification and treatment phases  
l Oxygen saturation (SpO 2) will be monitored continuously up to [ADDRESS_621049] study treatment administration in qualification phase  throughout the duration of study participation.  
Serious adverse events (SAEs) will be reported from the time of s igning informed consent through  the duration of study participation. Other conditions reported between the time 
of signing informed consent and first study treatment administration in the qualification phase will be recorded as medical history.  
Protocol No: Protocol No: AR26.3031.[ADDRESS_621050] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 14 of 84 
o Additional training sessions may be cond ucted as needed.  
p Subjective measures will be evaluated as follows:  
Category  Evaluations  Phase  Timepoints  
Drug -specific 
VAS  Drug Liking, Good Drug Effects, 
Bad Drug Effects, and Any Drug 
Effects  Qualification p hase approximately 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 * hours postdose  
Treatment p hase approximately 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, and 24 hours postdose  
Overall Drug Liking and Take Drug 
Again  Qualification and 
treatment p hases  approximately 12 and 24 hours postdose  
Other VAS  High, Feeling Drunk, 
Relaxation /Agitation , and 
Drowsiness/Alertness  Qualification p hase within 1 hour prior to and approximately 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 * hours postdose  
Treatment p hase within 1 hour prior to and approximately 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, and 24 hours 
postdose  
ARCI Scales  Morphine -Bezedrine  Group (MBG) 
and Pentobarbital –Chlorpromazine –
Alcohol Group (PCAG)  Qualification p hase within 1 hour prior to and approximately 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 * hours postdose  
Treatmen t phase within 1 hour prior to and approximately 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, and 24 hours 
postdose  
*[ADDRESS_621051] dose of the qualification phase is to be performed prior to the second dose of the qualificat ion phase.  
q Conducted during the qualification and treatment phases within 1 hour prior to dosing and approximately 0.5, 1, 1.5, 2, 3, 4, and 6 hours postdose.  
r Blood samples will be collected as indicated in Table 4Table 4. When clinical activities are scheduled to occur at the same time, pharmacodynamic data collection (vital signs , 
including spot EtCO 2, then subjective measures) is to be prioritized, followed by [CONTACT_483280].  
s Randomization will be performed for qua lification phase only on Day -1. Subjects who meet qualification criteria will be randomized for the treatment phase on Day -1 
(treatment phase ). 
t Subjects administered 20 mg oxycodone  or placebo according to randomization  with a minimum of 24 hours between doses during the qualification phase . 
u Subjects administered placebo, GE-IR 200 mg + oxycodone 20 mg, GE-IR 450 mg + oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg, or oxycodone 20 mg (minimum washout 
period of at least 3 days  between doses ). 
v Covid -[ADDRESS_621052] will be performed before each admission.  
 
Protocol No: AR26.3031.[ADDRESS_621053] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 15 of 84 
INVESTIGATOR AND STUDY ADMINISTRATIVE STRUCTURE  
SPONSOR ’S CONTACT :  [CONTACT_483281] D. Johnson, RN, BSN  
Director, Clinical Development  
Arbor Pharmaceuticals, LLC  
[ADDRESS_621054]  
Atlanta, GA [ZIP_CODE] [LOCATION_003]  
Office: 404 -496-5903; Cell 770 -314-3006  
E-mail:  [EMAIL_9293]  
PRINCIPAL INVESTIGATOR:   [INVESTIGATOR_85289], MD  
Altasciences  
[ADDRESS_621055] nue 
Overland Park, KS [ZIP_CODE] [LOCATION_003]  
CLINICAL RESEARCH UNIT :  Altasciences  
[ADDRESS_621056]  
Overland Park, KS [ZIP_CODE]  [LOCATION_003]  
CLINICAL LABORATORY   
FACILITY:     Quest Diagnostics  
[ADDRESS_621057]  
Lenexa, KS  [ZIP_CODE]  [LOCATION_003]  
BIOANALYTICAL  FACILITY : Altasciences  
[ADDRESS_621058].  
Laval, Quebec, Canada  
H7V 4B3  
MEDICAL WRITING &  
SCIENTIFIC AFFAIRS:   Altasciences  
[ADDRESS_621059] 
Laval, Quebec, Canada  
H7V 4B3  
STATISTICAL FACILITY : Altasciences  
[ADDRESS_621060] nue 
Mount -Royal, Quebec, Canada  
H3P 3P1  
DATA MANAGEMENT FACILITY:  Altasciences  
[ADDRESS_621061].  
Overland Park, KS [ZIP_CODE]  [LOCATION_003]  
Protocol No: AR26.3031.[ADDRESS_621062] Number: ABO -P4-[ADDRESS_621063] MANAGEMENT:   Altasciences  
[ADDRESS_621064] 
Laval, Quebec, Canada  
H7V 4B3  
 
COGNITIVE TESTS:  Cambridge Cognition  
[ADDRESS_621065]  
Park City, UT [ZIP_CODE], [LOCATION_003]  
 
MONITORING:  Randstad Life Sciences  
[ADDRESS_621066] North; Suite 120  
Deerfield, IL [ZIP_CODE]  
Protocol No: AR26.3031.[ADDRESS_621067] Number: ABO -P4-[ADDRESS_621068] prod rug in blood is transient and 
≤2% of the c orresponding gabapentin level. As a prodrug of gabapentin, its therapeutic effects in 
restless legs syndrome (RLS) and postherpetic neuralgia (PHN) are attributable to gabapentin.  
The mechanism of action by [CONTACT_483282], gabapentin prevents allodynia (pain -related behavior in response to a 
normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli).  
Gabapentin prevents pain -related responses in several models of neuropathic pain in rats and 
mice (e.g., spi[INVESTIGATOR_483237], spi[INVESTIGATOR_483238], and acute  herpes zoster 
infection model). Gabapentin also decreases pain -related responses after peripheral inflammation 
(carrageenan footpad test, late pha se of formalin test), but does not alter immediate pain -related 
behaviors (rat tail flick test, formalin footpad acute phase). The relevance of these models to 
human pain is not known.  
Gabapentin is structurally related to the neurotransmitter gamma -aminob utyric acid (GABA) but 
has no effect on GABA binding, uptake, or degradation. Gabapentin enacarbil and gabapentin 
have been tested in radioligand binding assays, and neither exhibited affinity for a number of 
other common receptor, ion channel, or transpor ter proteins.  
In vitro studies have shown that gabapentin binds with high affinity to the α2δ subunit of 
voltage -activated calcium channels; however, the relationship of this binding to the therapeutic 
effects of gabapentin enacarbil in RLS and PHN is unkn own.  
1.2. Study Rationale  
The primary purpose of this study is to evaluate the abuse potential of gabapentin enacarbil 
immediate -release (GE -IR), the active moiety in Horizant, taken alone and taken in combination 
with oxycodone, compared to that of oxycodone a lone. 
Gabapentin does not exhibit affinity for benzodiazepi[INVESTIGATOR_050], opi[INVESTIGATOR_2573] (mu, delta, or kappa), or 
cannabinoid [ADDRESS_621069] of the individuals described in these  reports had a history of 
poly-substance abuse or used gabapentin to relieve symptoms of withdrawal from other 
substances.  
The Arbor drug safety database through June 2019 contained 606 reports categorized under drug 
abuse. Of these, 13 (2.1%) were attribu ted to Horizant, 344 to gabapentin, and 249 to Regnite 
(gabapentin enacarbil reports in Japan). Of the [ADDRESS_621070] misuse and use issue cases (n=6, 46%). These cases involved 
consumers who report ed adjusting their own dose to manage their own symptoms/tolerability. 
This was followed in frequency by [CONTACT_268582] (n=4, 31%). The overdose cases involved reports of 
Protocol No: AR26.3031.[ADDRESS_621071] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 18 of 84 
being jittery after taking 1200 mg, short -term memory loss after increasing the dose from 
1200 mg to 1800 mg, and sedation after taking 600 mg instead of 300 mg. The fourth overdose 
case involved a male who took several pi[INVESTIGATOR_483239]. The  remaining  3 cases  of Horizant -related  abuse involved  accidental 
overdose (n=2) and dependence (n=1) and contained limited information in each case . The 
Regnite cases involved similar events, with intentional product misuse and use issue cases 
accountin g a larger majority of cases ( 6%). 
Gaba pentin abuse cases were different,  however. The most common event was toxicity to 
various agents with (97.7%). Of the 336 cases that involv ed toxicity to various agents  more 
specificity was provided in 86 of the cases. These 86 cases also included accidental  overdose 
(n=51), drug abuse (n=21), overdose (n=8), and intentional product misuse (n=4), intentional 
overdose (n=1), and cardiorespi[INVESTIGATOR_13374] (n=1). With the exception of  toxicity to various 
agents, no term w as reported more than [ADDRESS_621072] been no Horizant reports from the 
American Association Poison Control Centers National Poison Data System Annual Report.  
In addition , the Food and Drug Administration’s Adverse Event Reporting System (FAERS) 
from October 2012 to December 2016 reportedly co ntained 634 gabapentinoid abuse -related 
reports (10.2% of  all adverse drug event [ADE] reports ). Of these, abuse  was associated with 
5.7%  of total reports for gabapentin  ADEs (576 of 10,038 ) compared to 10.2%  of total reports 
for pregabalin  ADEs (58 of 571) . The abuse -related proportional reporting rate of pregabalin to 
gabapentin is 1.77. Abuse was more common relative to the total ADEs reported with pregabalin 
than gabapentin .2 
Further,  per FAERS update (cumulative to June  30 2019),  the proportional reporting ratio (PRR) 
of gabapentin versus gabapentin enacarbil abuse related events was 2.22 [calculated as 
(Ga/Gt)/(GEa/GEt) = (576/100 38)/(55/2128)]. This indicates that the number of abuse -related 
events in relation to the number of reported ADEs is greater for gabapentin compared to 
gabapentin enacarbil.  
Regardless of reported abuse , drugs that affect the central nervous system ( CNS ), are chemically 
or pharmacologically similar to other drugs with known abuse potential, or produce psychoactive 
effects are required to undergo assessments related to their abuse potential.3, 4 Horizant, a 
CNS -active drug, is currently approved for use in humans as a treatment for moderate to severe 
primary RLS and PHN ; however, its abuse pot ential has not been formally evaluated . 
This study is a randomized, double -blind, active - and placebo -controlled, 6-way crossover 
design, aimed to assess the abuse potential, safety, and PK of GE-IR doses when administered 
alone or in combination with an opi[INVESTIGATOR_483231] (oxycodone), and comp ared to placebo and 
oxycodone intake alone, in healthy, nondependent, recreational opi[INVESTIGATOR_45157]. The overal l design 
is consistent with [LOCATION_002] (US)  Food and Drug Administration (FDA) guidelines for 
human abuse potential (HAP) assessment.4, 5 
Further, gabapentin abuse is reported both alone (i.e., without other drugs), and in conjunction 
with opi[INVESTIGATOR_483240] ‘high’ obtained from opi[INVESTIGATOR_2438].22, 23,24  This study is thus designed with 
the goal of characterizing any additive or synergistic effects on the abuse potential and 
physiologic effects of co -administered GE-IR and opi[INVESTIGATOR_2480].  
Protocol No: AR26.3031.[ADDRESS_621073] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 19 of 84 
Because of inter -individual variability in subjective responses, HAP  studies are typi[INVESTIGATOR_483241] -blind crossover studies including the investigational drug and active 
control, as well as placebo. In this study, immediate -release (IR) oxycodone 20 mg (oral) wi ll be 
administered during the qualification and treatment phases, given that this dose is used by 
[CONTACT_483283], is within the range of recommended label doses , and is supported by 
[CONTACT_483284] .27, [ADDRESS_621074] ion and evaluation of clinical endpoints . 
The subjects in this study will be healthy individuals with previous nontherapeutic (recreational) 
experience with opi[INVESTIGATOR_2438]. These subjects represent the population at greater risk for abuse of the 
drug and can prov ide meaningful ratings of the drug experiences with a lower risk of false 
negative results; therefore, they are the population with the most face validity. In addition to the 
requirement that subjects are “history qualified” (i.e., history of recreational opi[INVESTIGATOR_2441]), subjects 
will also be required to pass a pharmacologic qualification. In an abuse potential study, a 
negative result with a non -drug-using population can be considered inconclusive, since these 
subjects often do not like the effects of drugs t hat are readily abused by [CONTACT_483285] .4, 7 
A double -blind qualification phase has been included in the study design as an enr ichment 
procedure to ensure that study subjects are not opi[INVESTIGATOR_74460] (through a naloxone challenge) 
and that subjects who meet the drug use history criteria can also distinguish the subjective effects 
of the active control (i.e., oxycodone) from placeb o. The pharmacologic qualification procedure 
provides more objective confirmation of drug use history, ensures that subjects can respond 
appropriately in a clinical setting, and reduces the chance of a false positive response to placebo. 
The washout betwee n treatments in the qualification phase is consistent with previous studies of 
this type.  
The 3-day washout interval between the qualification phase and treatment phase is considered  
sufficient to ensure complete washout of  oxycodone . Given the T ½ of gabap entin when receiving 
GE-IR (4.38 - 5.47 hours) and oxycodone (approximately 3-5 hours)27 following oral 
administration , the 3 -day interval between study treatment administrations  will ensure sufficient 
washout of GE-IR and oxycodone.  
Based on the pharmacokinetic ( PK) profile of gabapentin , the 24 -hour assessment period 
following administration of study drug during the treatment p hase is sufficient to evaluate the 
safety and tolerability and to capture the profile of pharmacodynamic ( PD) effects.  
The selection of subjective abuse potential measures in this study, includin g the use of maximum 
(peak) effect ( Emax) of the “at this moment” Drug Liking visual analog scale (VAS; administered 
as a bipolar scale) as a primary endpoint,  is consistent with regulatory guidelines.[ADDRESS_621075]’s 
willingness to take the drug again.  
Protocol No: AR26.3031.[ADDRESS_621076] Number: ABO -P4-[ADDRESS_621077] ry on the assessment of abuse 
potential of drugs  recommends including multiple doses of the study treatment in the HAP  study, 
ranging from therapeutic to supratherapeutic.4 
The GE -IR doses in this study will include 200 mg and 450 mg doses, in order to evaluate the 
dose response of the drug. These doses of GE -IR correspond to the C max values produced by 
[CONTACT_483286] 600 mg and1200 mg Horizant i n healthy individuals.  
Oxycodone is the selected positive control for this study. The dose of oxycodone  selected 
(20 mg) will be used per the recommendations of the Food and Drug Administration (FDA) and 
has been well tolerated in the study population .26, 30, 31 
1.4. Risk/Benefit Assessment  
1.4.1.  Known Potential Risks  
The safety of GE -IR in doses ranging from 350 mg to 2800 mg has been evaluated in 88 healthy 
subjects in 2 clinical trials (single ascending dose trial [XP 006] and multiple ascending dose 
trial [XP 018]).  
In study XP 006, dizziness was the most common AE experienced and appeared to be dose -
dependent; occurring mostly at doses from [ADDRESS_621078] common AE experienced, followed by 
[CONTACT_12704], somnol ence and nausea. Adverse events were mild with frequencies that were possibly 
dose-related.  
The doses of GE -IR administered in this study are not anticipated to induce any potential risk to 
the subjects. Single dose studies using up to 2800 mg of GE -IR (XP  006) as mentioned above did 
not result in any respi[INVESTIGATOR_483242]. The safety monitoring 
practices employed by [CONTACT_256563]’ safety and to detect any 
treatment -emergent AEs (TEAEs).  
The fo llowing safety measures will be monitored continuously for signs of respi[INVESTIGATOR_113021] 1 hour prior to dosing up to approximately 6 hours following dosing in the treatment 
phase:  
• end-tidal CO 2 (EtCO 2) monitoring  
• blood oxygen saturation (SpO 2) monitoring  
• respi[INVESTIGATOR_483243] [ADDRESS_621079] in monitoring respi[INVESTIGATOR_4806], 
change in oxygenation, and change in ventilation.38,39,40,41 Monitoring ETCO 2 has been shown to 
Protocol No: AR26.3031.[ADDRESS_621080] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 21 of 84 
be more sensitive in detection of respi[INVESTIGATOR_483244] .42 
In the clinical setting, respi[INVESTIGATOR_483245], decreased SpO 2 levels,  or elevated ETCO 2 levels 42 and, therefore, these 
measures are appropriate to monitor respi[INVESTIGATOR_2341].  
Additional safety measures implemented  at predose and specified timepoints postdose will 
include the collection and documentation of AEs and vital signs (i.e.,  systolic and diastolic blood 
pressure, pulse rate, respi[INVESTIGATOR_697], oral temperature, SpO 2, and ETCO 2. Subjects will be 
determined as  healthy for inclusion into the study based on measures of clinical laboratory 
testing, vital signs, medical history, C -SSRS, physical examination, and ECG.  
1.4.2.  Known Potential Benefits  
As the study treatment s are not being given to subjects to treat any symptoms or illness, there 
will be no direct medical benefit from participation in this trial.  
Protocol No: AR26.3031.[ADDRESS_621081] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 22 of 84 
2. STUDY OBJECTIVES  AND ENDPOINTS  
The primary and secondary objectives of the study and corresponding endpoints are:  
OBJECTIVES  ENDPOINTS  
Primary   
To evaluate the  abuse potential of single oral 
doses of GE -IR taken in combination with an 
opi[INVESTIGATOR_483231] (oxycodone) in healthy, 
nondependent, recreational opi[INVESTIGATOR_45155].  The primary endpoint of this study will be E max over 
24 hours for Drug Liking (“at this momen t”), assessed 
on a bipolar (0 to 100 points) VAS . 
Key Secondary PD endpoints will be:  
• Overall Drug Liking VAS (E max) 
• Take Drug Again VAS (E max) 
• High VAS (E max) 
Non-Key Secondary PD endpoints will be:  
Balance of Effects  
• Drug Liking VAS ( minimum effect [ Emin], 
time of maximum effect [ TE max], time of 
minimum effect [ TE min] and area under the 
effect -time curve [ AUE ])  
Positive Effects  
• Good Effects VAS (E max, TE max, and 
TA_AUE)  
• High VAS (TE max, and TA_AUE)  
Negative Effects  
• Bad Effects VAS (E max, TE max, and TA_AUE)  
Other Subjective Effects  
• Any Effects VAS (E max, TE max, and 
TA_AUE)  
• Feeling Drunk (E max, TE max, and TA_AUE)  
• Drowsiness/Alertness VAS (E min, TE min, and 
area over the effect -time curve [TA_AUE])  
• Relaxation/Agitation VAS (E min, TE min, and 
area over the effect -time curve [TA_AUE])  
• Addiction Research Center Inventory (ARCI) 
Morphine -Benzedrine Group (MBG) Scale 
(Emax, TE max, and TA_AUE)  
• ARCI Pentobarbital –Chlorpromazine –
Alcohol Group (PCAG) Scale (E max, TE max, 
and TA_AUE)  
Observer Assessments  
• Modified Observer’s Assessment of 
Alertness/Sedation (MOAA/S; E min, change 
from baseline to minimum effect [CFB min], 
and TA_AUE)  
 
 
Protocol No: AR26.3031.[ADDRESS_621082] Number: ABO -P4-[ADDRESS_621083] measurable observed concentration 
(AUC 0-t), and area under the curve from time 0 to 
infinity (AUC 0-inf) 
To evaluate the effects on safety and 
tolerability of single oral doses of GE -IR 
taken alone or in combination with 
oxycodone, compared to placebo and 
oxycodone alone, in healthy nondependent, 
recreational opi[INVESTIGATOR_45155].  Secondary endpoints will include  a summary of the 
incidence of AEs, serious adverse events (SAEs), as 
well as descriptive summary and statistics of the 
safety parameters, which include clinical laboratory 
values, vital signs (i.e.,  systolic and diastolic blood 
pressure, pulse rate, respi [INVESTIGATOR_697], oral temperature, 
oxygen saturation [SpO 2]), continuous SpO 2 
monitoring, continuous End Tidal CO 2, 
electrocardiograms (ECGs), Columbia Suicide 
Severity Rating Scale (C -SSRS), and physical 
examination findings.  
3. STUDY DESIGN  
3.1. Overall  Study Design  
This study will be a randomized, double -blind, active - and placebo -controlled, [ADDRESS_621084] of 4 phases: screen ing, q ualifica tion, treatment, and follow -up. The study 
schema is presented in Figure 1Figure 1. 
3.1.1.  Screening and Qualification Phase  
After a screening period of up to 30 days, eligible subjects will be admitted to t he clinica l 
research unit (CRU) on Day -[ADDRESS_621085] 
will be administered in the following 2 steps:  
1. Naloxone 0.2 mg will be given via intraveno us (i.v.) bolus followe d by a [ADDRESS_621086] will be observed for 1 minute after bolus administration for signs or 
symptoms of withdrawal.  
Protocol No: AR26.3031.[ADDRESS_621087] Number: ABO -P4-[ADDRESS_621088] will be observed for an additional 5 minutes.  
The naloxone doses selected for the challenge are consistent with doses commonly administered 
to confirm opi[INVESTIGATOR_483246].  The Clinical Opi[INVESTIGATOR_2433] (COWS)[ADDRESS_621089] any signs or symptoms of opi [INVESTIGATOR_483247] 1 (predose and 1 minute 
after administration) and step 2 (5 minutes after administration) of the naloxone challenge  test. 
Subjects who present symptoms of withdrawal during predose assessment or following 
administration of the naloxone challenge (i.e., COWS score ≥5, unless in the opi[INVESTIGATOR_483248]) wil l be excluded from 
the study and will not be eligible to enter the qualification phase.  
The qualification phase will  further  determine whether subjects like and tolerate the effects of 
oxycodone, and can discriminate these from placebo; this visit will als o determine if each subject 
is suitable for entry into and is likely to complete the treatment phase (i.e. likely to comply with 
the study protocol).  
On Days 1 and 2  of the qualification phase , subjects will receive the following treatments in a 
randomized , double -dummy, crossover manner  as further detailed in section 3.2: 
 Day 1  Day 2  
Sequence 1  Treatment X:  
Placebo  Treatment Y:  
Oxycodone 20 mg 
Sequence 2 Treatment Y: 
Oxycodone 20 mg Treatment X: 
Placebo  
Each dose will be separated by [CONTACT_3450] [ADDRESS_621090] meet all of the qualification criteria  (see section 4.3) to be randomized for 
participation in the trea tment phase.  
It is preferred that subjects remain confined at the CRU from the start of the qualification phase 
through completion of the treatment phase;  however, subjects may be discharged between these 
phases if required. Appropriate discharge and re -admission proce dures are noted in Table 1Table 
1. 
3.1.2.  Treatment Phase and Follow -Up 
The treatment phase is a randomized, double -blind, active - and placebo -controlled, [ADDRESS_621091] 
crossover design in which subjects will receive the following 6 treatments in a crossover manner 
and blinded fashion, as further detailed in section 3.2: 
• Treatment A: Placebo  
• Treatment B: Oxycodone 20 mg 
• Treatment C: GE-IR 200 mg + oxycodone 20 mg 
• Treatment D: GE-IR 450 mg + oxycodone 20 mg 
Protocol No: AR26.3031.[ADDRESS_621092] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 25 of 84 
• Treatment E: GE-IR 200 mg 
• Treatment F: GE-IR 450 mg  
Each study treatment administration will be separated by 3 days. Drug administration s will be 
followed by [CONTACT_4002], PK, and safety assessments for up to 24  hours postdose. Subjects will be 
discharged from the investigational site approximately 24  hours after the final dose  of the 
treatment phase,  if deemed medically sta ble for discharge by [CONTACT_2413]. A follo w-up visit 
will occur 7 days (±2  days) following the final dose . 
Study assessments will be performed at the timepoints outlined in the Schedule of Activities 
(Table 1Table 1). 
The maximum duration of subject participation, including screening, will be approximately 
59 days. 
Subjects who terminat e the study early will perform f ollow -up procedures at the time of early 
termination ( ET). 
Protocol No: AR26.3031.[ADDRESS_621093] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 26 of 84 
Figure 1. Study Schema  
 Screening   
  
 Admission within 30 days of screening  
  
 Qualification Phase  - Naloxone Challenge  
(Day -1)  
  
 ↕ 24 hours  
  
 Qualification Phase - Randomized Double -Blind 
Discrimination  
(crossover treatments on Day 1 and Day 2)  
  
 Treatment X 
Placebo  ↔ 
24 hours  Treatment Y 
Oxycodone 20 mg  
  
 ≥[ADDRESS_621094] 
treatment phase treatment  
  
Randomized Double -Blind Treatment Phase  
(6 crossover treatment periods)  
  
Treatment 
A 
Placebo  ≥3 
days Treatment B  
Oxycodone  
20 mg ≥3 
days Treatment C  
GE-IR 
200 mg 
+ 
Oxycodone  
20 mg  ≥3 
days Treatment D  
GE-IR 
450 mg 
+ 
Oxycodone  
20 mg g ≥3 
days Treatment E  
GE-IR  
200 mg 
 ≥3 
days  Treatment F  
GE-IR  
450 mg  
 
  
 Follow -Up Visit  
(7 ±[ADDRESS_621095] study drug administration)   
 
Note: the sequence of treatments shown is for illustration of the overall design and does not necessarily represent an 
actual treatment sequence.  
Protocol No: AR26.3031.[ADDRESS_621096] Number: ABO -P4-[ADDRESS_621097] of 1 capsule containing oxycodone or 
placebo. The following treatments will be administered  orally with approximately 240 mL of 
room temperature water in the morning under fasted conditions : 
• Treatment X (Placebo): 2 × placebo tablets over -encapsulated to match oxycodone  
• Treatment Y (Active Control): 2 × [ADDRESS_621098] of 2 capsules of GE-IR and/or placebo to 
match GE-IR to achieve assigned dose plus 2 capsule s containing oxycodone or placebo. The 
following treatments will be administered orally with approximately 240 mL  of room 
temperature water in the morning under fasted conditions : 
• Treatment A (Placebo):  
2 × placebo capsules to match GE-IR and 2  × placebo tablets over -encapsulated to match 
oxycodone  
• Treatment B (Active Control):  
2 × placebo capsules to match GE -IR and 2 × 10 mg oxycodone tablets over -
encapsulated  
• Treatment C ( GE-IR 200 mg + Oxycodone):  
1 × 200 mg GE-IR capsules , 1 × placebo capsules to match GE-IR, and 2 × 10 mg 
oxycodone tablets over -encapsulated  
• Treatment D ( GE-IR 450 mg + Oxycodone):  
2 × 225 mg GE -IR capsules and 2 × 10 mg oxycodone tablets over -encapsulated  
• Treatment E ( GE-IR 200 mg): 
1 × 200 mg GE -IR capsules, 1 × placebo capsules to match GE -IR, and 2 × placebo 
tablets over -encapsulated to match oxycodon e 
• Treatment F (GE -IR 450 mg):  
2 × 225 mg GE -IR capsules and 2  × placebo tablets over -encapsulated to match 
oxycodone  
4. SUBJECT POPULATION  
Subjects who meet  all the inclusion criteria and none of the exclusion criteria at the screening 
visit may be eligible for participation in this study.  Continued eligibility will be assessed upon 
admission to the clinical site , prior to the first study treatment administration . 
Screen failures are defined as subjects who consent to participate in the clinical trial but are not 
subsequently randomly assigned to treatment in the qualification phase. Subjects who enter the 
qualification phase and fail to qualify for the treatment phase will be considered qualification 
failures.  
Protocol No: AR26.3031.[ADDRESS_621099] Number: ABO -P4-[ADDRESS_621100] mee t all of the following criteria to be enrolled:  
1. Provision of signed and dated informed consent form  (ICF) , 
2. Stated willingness to comply with all study procedures and availability for the duration of 
the study , 
3. Male or female , between  18 and 55 years  of age, inclusive , 
4. Current nondependent, recreational opi[INVESTIGATOR_483249] (nontherapeutic) purposes (i.e., for psychoactive effects) at least [ADDRESS_621101]’s lifetime  and at least once in the last 12 weeks,  
5. Body mass index (BMI) within 18.0 kg/m2 to 36.0 kg/m2, inclusive,  
6. If female, meets 1 of the following criteria:  
a) If of childbearing potential agrees to use [ADDRESS_621102] dose of the study treatment . An acceptable method of 
contraception includes 1 of the following:  
• Abstinence from heterosexual intercourse , 
• Hormonal contraceptives (birth control pi[INVESTIGATOR_3353], injectable/implant able/insertable 
hormonal birth control products, transdermal patch) , or 
• Intrauterine device  (IUD; with or without hormones) . 
 
Or 
 
b) If of childbearing potential agrees to use a double barrier method (e.g., condom and 
spermicide) during the study and for at least [ADDRESS_621103] dose of study 
treatment . 
Or 
c) If of non -childbearing potential, defined as surgically sterile (i.e ., has undergone 
complete hysterectomy, bilateral oophorectomy  or tubal ligation) or is in a 
postmenopausal state (i.e. , at least 1 year without menses without an alternative 
medical condition and confirmed follicle stimulating hormone [FSH] ≥ 40 mIU/mL 
prior to the first study treatment  administration) , 
7. If male  and engaging in sexual activity that has the risk of pregnancy must agree to use a 
double barrier method (e.g.,  condom and spermicide)  and agree to not donate sperm 
during the study and for at least  [ADDRESS_621104] dose of study treatment , a male who 
has a pregnant partner shall be excluded,  
Protocol No: AR26.3031.[ADDRESS_621105] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 29 of 84 
8. Healthy, as determined by [CONTACT_237062], 
physical examination, 12 -lead ECG, vital signs or clinical laboratory ( including 
hematology, clinical chemistry, urinalysis, and serology [screening visit only]) at 
screening visit and admission, in the opi[INVESTIGATOR_85292] . 
9. Negative Covid -[ADDRESS_621106] prior to each admission . 
4.2. Exclusion Criteria  
Subjects meeting the followin g criteria will be excluded from participation:  
1. History of significant hepatic, renal, cardiovascular, pulmonary, hematologic, 
neurological, psychiatric, gastrointestinal, endocrine, immunologic, ophthalmologic, or 
dermatologic disease  of any etiology (including infections),  
2. Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that 
may affect drug bioavailability  with the ex ception that cholecystectomy is  permitted at 
the discretion of an investigator , 
3. Presence of any significant respi[INVESTIGATOR_483250] (e.g., upper respi[INVESTIGATOR_4375], sleep apnea, emphysema, asthma) at 
screening (subjects with acute respi[INVESTIGATOR_483251]),  
4. Personal or  family history (first degree relatives) of allergy, hypersensitivity, or drug rash 
with eosinophilia and systemic symptoms ( DRESS ) syndrome to gabapentin enacarbil, 
gabapentin  or any drug product includ ing naloxone, opi[INVESTIGATOR_2438] (e.g., oxycodone ), or related 
drugs or known excipi[INVESTIGATOR_483252] (e.g. lactose),  
5. History of sensitivity to or poor tolerance of gabapentin enacarbil, gabapentin, 
pregabalin, naloxone , or oxycodone , 
6. Female who is lactating at screening , 
7. Female who is pregnant according to the pregnancy test at screening or prior to the first 
study treatment  administration  or planning to become pregnant within [ADDRESS_621107] study treatment  administration , 
8. History of substance or alcohol dependence (excluding nicotine and caffeine) within the 
past 2 years, as defined by [CONTACT_92678], 4th 
Edition (DSM -IV), and/or subject has ever  been in a drug or alcohol rehabilitation 
program  within the last 2 years , 
9. Subjects with positive UDS results at screening and admission will be assessed for 
inclusion at the discretion of an Investigator. If tetrahydrocannabinol (THC) is positive at 
Protocol No: AR26.3031.[ADDRESS_621108] Number: ABO -P4-[ADDRESS_621109] may be rescheduled, in the 
opi[INVESTIGATOR_871],  
10. Is a heavy smoker (>20 cigarettes per day  or nicotine -equivalent ) and/or is unable to 
abstain from smoking or unable to abstain from the use of prohibited nicotine -containing 
products for  at least 1 hour  before and 6 hours after study treatment  administration 
(including  e-cigarettes, pi[INVESTIGATOR_27442], cigars, chewing tobacco, nicotine topi[INVESTIGATOR_113040], nicotine 
gum, or  nicotine lozenges ), 
11. Is a heavy opi[INVESTIGATOR_483253] a 20 mg dose of oxycodone, in the 
opi[INVESTIGATOR_483254],  
12. Regularly consumes excessive amounts of caffeine or xanthines within 30 days prior to 
screening, defined as greater than 6  servings (1  serving is approximately equiva lent to 
120 mg of caffeine) of coffee, tea,  cola, or other caffeinated beverages per day,  
13. History of suicidal ideation or suicidal behaviour within 2 years of screening, showing 
suicidal tendency as per the Columbia Suicide Severity Rating Scale (C-SSRS) 
administered at screening  (APPENDIX 7APPENDIX 7 ), or is currently at risk of suicide 
in the opi[INVESTIGATOR_85292],  
14. Presence of clinically significant ECG abnormalities  at the screening visit,  as defined by 
[CONTACT_35846] , NOTE: QT corrected according to Fridericia's formula (QTcF) 
interval of >450 msec in male subjects or >470 msec in female subjects will be  
exclusionary. The ECG may be repeated once for confirmatory purposes if the initial  
value obtain ed exceeds the limits specified,  
15. Has creatinine clearance ≤60ml/min as calculated by [CONTACT_16424] -Gault equation,  
16. Any history of tuberculosis , 
17. Positive screening results to human immunodeficiency virus  (HIV)  1 and 2 antibod ies, 
hepatitis B virus surface a ntige n (HBsA g) or hepatitis C v irus antibody (HCV Ab) tests , 
18. Intake of an investigational product (IP) within 30 days or 5 times the half -life 
(whichever is longer) prior to screeni ng, 
19. Use of any prescription drugs  (with the exception of hormonal contraceptives or hormone 
replacement therapy) in the [ADDRESS_621110] as 
healthy,  
Protocol No: AR26.3031.[ADDRESS_621111] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 31 of 84 
20. Use of over -the-counter (OTC) products (including herbal preparations and supplements) 
within [ADDRESS_621112] study treatment administration, with the exception of 
ibuprofen or acetaminophen,  
21. Use of a prohibited medication  as specified in section 4.7, 
22. Donation of plasma in the 7 days prior to screening , 
23. Blood d onation (excluding plasma) of approximately [ADDRESS_621113] not present symptoms of withdrawal d uring predose assessment or following 
administration of the naloxone challenge (i.e., COWS score <5).  
4.4. Qualification Criteria for Treatment Phase  
Subjects must meet the following criteria to be considered eligible for enrollment in the  
treatment p hase of th e study:  
1. Peak score  of at least 65 points in response to oxycodone 20 mg and greater than that of 
placebo on  the Drug Liking VAS (difference of at least 15 points), with a peak score of at 
least 65 points for oxycodone . 
2. Acceptable placebo response based on Drug Liking  VAS (score s between 40 and 
60 points, inclusive).  
3. Acceptable overall responses to oxycodone  and placebo on the subjective measures, as 
judged by [CONTACT_91048].  
4. Able to tolerate the [ADDRESS_621114] difficulty differentiating between bipolar and unipolar VAS 
(e.g., making errors such as selecting 50 as neutral for a unipolar scale) or difficulty 
distinguishing between "at this moment" and "next -day" measures during the 
qualification phase may be permitted into the treatment p hase, and will undergo 
additional training on the difference between the scale types.  Additional training sessions 
will be documented in source files.  
Protocol No: AR26.3031.[ADDRESS_621115] Number: ABO -P4-[ADDRESS_621116] treatment  administration  of the qualification phase  (oxycodone or placebo) , 
inclusion/exclusion criteria will govern the subjects to be dosed. Subjects withdrawn before first 
treatment administration of the qualification phase will n ot be followed up and will not undergo 
ET assessments. Other safety assessments may be performed if required.  
Subjects are free to withdraw their consent to participate in the study at any time, without 
prejudice. The reason for their withdrawal or for dec iding to end their participation will be 
documented.  
4.5.2.  After First Treatment Administration  
Subjects may, at any time, voluntarily withdraw from the study or be removed from the study at 
the discretion of an investigator or s ponsor. An investigator may withdraw a subject at any time 
if it is determined that continuing the study would result in a significant safety risk to the subject 
or if their behavior is deleterious to the study environment.  
If such withdrawal occurs, or if the subject fails to return for visits, an investigator should 
determine the primary reason for a subject’s premature with drawal from the study and record the 
reason in the subject’s study documents.  
Attempts should be made and documented to have such subjects  complete the ET assessments. 
Early t ermination assessments should be performed as soon as possible after the last st udy 
treatment administration.  
The blind may be broken only in emergency situations, where knowledge of the treatment that 
the subject received is ne cessary for safety management (s ection  5.2.4 ) 
Details of reasons for removal of subjects will be recorded, reported to the sponsor and 
documented in the clinical study report  (CSR) . 
For subjects who are lost to follow -up (i.e. , those subjects whose status is unclear because they 
fail to appear for study visits without stating an intention to withdraw), an investigator should 
show "due diligence" by [CONTACT_483287]  
(e.g., dates of telephon e calls, registered letters) . 
4.6. Lifestyle and/or Dietary R equirements  
• Subjects will be prohibited from consuming  food or bevera ges containing grapefruit,  
pomelo , pomegranate, star fruit, Seville orange, poppy seeds, and quinine (i.e., tonic 
water) for [ADDRESS_621117] study treatment administration  and throughout the 
study . 
• Subjects will be prohibited from consuming alcohol for [ADDRESS_621118] for alcohol  and/or a drug screen  may be performed if requested by [CONTACT_98225] . If a subject presents with a positive alcohol test or drug screen at any visit 
after the screening visit, the subject may be rescheduled at the di scretion of an 
Protocol No: AR26.3031.[ADDRESS_621119] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 33 of 84 
investigator. If THC is positive at check -in, a cannabis intoxication evaluation will be 
done by [CONTACT_2413], and inclusion will be at his or her discretion.  
• Subjects will be prohibited from consuming  food or beverages containing xanthines 
(i.e., tea, coffee, cola drinks, energy drinks or chocolate) for [ADDRESS_621120] 
study treatment through clinic discharge.  
• Subjects will eat only the food provided by [CONTACT_113102].  
• Subjects will be asked to abstain from strenuous physical activity f or 48 hours prior to 
screening and pr ior to each admission to the CRU  and during inpatient stays.  
• During the study , smokers  will abstain from smoking for at least [ADDRESS_621121] 6 hours after each drug administration . Subjects will not be permitted to use other 
nicotine -containing products (including nicotine topi[INVESTIGATOR_113040], nicotine gum, or 
nicotine lozenges).  
• Subjects will be asked to refrain f rom driving, operating machinery, or engaging in 
hazardous activities until they and an investigator are convinced the study drug is not 
impairing their judgment and/or ability to perform skilled tasks.  
• Female subjects  of childbearing potential will have t o take appropriate measures to 
prevent pregnancy as described in section 4.1. It is the subject’s responsibility to notify 
the CRU  if a pregnancy occurs from the end of their study participation  until [ADDRESS_621122] dose of the study drug . 
• Males who engage in sexual activity that has a risk of pregnancy will be expected to use 
an acceptable con traceptive regimen  and not to donate sperm  from the first study 
treatment administration , during the study, and until at least [ADDRESS_621123] been completed.  
Systemic contraceptives and hormone replacement therapy are permitted for female subjects.  
Subjects will be asked about any new medications (including herbal preparations and 
supp lements) taken between screening and admission to the clinic , and between the qualification 
and treatment phase if a subject is discharged during this interim period . Information on any 
concomitant medications administered will be collected daily while subjects are in the clinic. All 
medications and significant non -drug therapi[INVESTIGATOR_014] (including physical therapy and blood 
transfusions) administered after the subject has received the study treatment must be listed in the 
subject case report form (CRF) an d related conditions (e.g., AEs) documented. The drug name 
[CONTACT_483313]. An investigator and/or the sponsor will decide whether the subject 
will be permitted to remain in the study, depending on the drug used, the time of drug intake, etc.  
Protocol No: AR26.3031.[ADDRESS_621124] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 34 of 84 
5. STUDY  TREATMENTS  
5.1. Investigational Products  
The lot number and the measured content of each dosage form ulation  will be included in the 
final report.  
5.1.1.  Gabapentin Enacarbil  
Gabapentin enacarbil immediate release capsules (GE -IR) will be provided by [CONTACT_483288], LLC for oral administration, and will be provided in opaque capsules of a 
suitable size to contain all study doses in order to maintain the blind during dosing.  
Placebo capsules matched to GE -IR will be supplied by [CONTACT_456]. The weight is mat ched to 
the sponsor’s GE -IR 225 mg capsule and the composition is the same . Placebo will be filled with 
225 mg of calcium phosphate dibasic dihydrate in the capsules. Patheon will take into 
consideration the client’s request for the same opaque and simple in color capsule to encapsulate 
both the active and placebo strengths . 
5.1.2.  Oxycodone  
Oxycodone IR will be supplied as 10 mg tablets , and over -encapsulated . 
Placebo to match oxycodone  tablets will be over -encapsulated 100 mg lactose tablets.  
Both products may be obtained by [CONTACT_483289] -encapsulated with the same 
capsules (Swedish Orange Opaque AAE -DB capsules [Capsugel] or similar) to maintain study 
blinding.  
5.2. Investigation al Product Management  
5.2.1.  Packaging, Labeling and Dispensing  
The sponsor will be responsible for ensuring that the study drug  is manufactured in accordance 
with applicable current Good Manufacturing Practice (cGMP) regulations and requirements.  
The study drug  will be labeled according to the requirements of local law and legislation. The 
study drug  will be dispensed according to International Council for Harmonisation (ICH) Good 
Clinical Practice (GCP)  by [CONTACT_483290]’s (CRU ’s) pharmacy, unless th e sponsor 
supplies the pharmacy with pre -labeled individual dosing samples.  
5.2.2.  Storage and Handling  
Once received, all study drugs will be stored in the CRU’s pharmacy.  
Gabapentin enacarbil immediate release (GE -IR) capsules and placebo should be stored at 25 °C 
with excursions between 15°C and 30°C allowed. Both placebo to match oxycodone  and 
oxycodone  should be stored between 15°C and 30°C. All study drugs should be kept in a tightly 
closed container, with provided desiccants, to protect from moisture. The products should not be 
used if expi[INVESTIGATOR_483255].  
The CRU’s pharmacy  will maintain  an inventory record of the study drugs  received, stored (in a 
secure restricted area), and dispensed. Study drugs  will be provided to study subjects only.  
Protocol No: AR26.3031.[ADDRESS_621125] Number: ABO -P4-[ADDRESS_621126] that the study is balanced. Once generated, the randomization 
code s will be final and will not be modified.  
Subjects who sign the ICF, are randomized but  do not receive a study treatment in the treatment 
phase may be replaced. Subjects who sign the ICF, are randomized and receive a study treatment 
in the treatment phase, and subsequently withdraw, or are withdrawn or discontinued from the 
study, may be rep laced. Replacement subjects will be assigned a new randomization number 
equivalent to the Treatment randomization + 1000 (e.g., 3000 series).  
Subjects who enter the treatment phase will be assigned a unique treatment randomization 
number. Subjects will be randomized to [ADDRESS_621127] to avoid confusion (e.g., 1000 series and 2000 series).  
[IP_ADDRESS].  Qualification Phase  
Subjects who enter  the qualification phase will be assigned, in ascending order, a qualification 
randomization number to identify the sequence of their treatments ( Table 2Table 2 ). 
Table 2 Sample Qualification Phase Sequences  
Treatment Sequence  Day 1  Day 2  
XY X Y 
YX Y X 
Treatment X: Placebo  
Treatment Y: Oxycodone 20 mg 
[IP_ADDRESS].  Treatment Phase  
For the treatment phase, qualified subjects will be randomized to [ADDRESS_621128] based 
on their randomization code. Subjects will receive all 6 treatments in the order specified by [CONTACT_483291] 6 x 6 Williams Square  (Table 3Table 3 ). 
Protocol No: AR26.3031.[ADDRESS_621129] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 36 of 84 
Table 3 Sample Treatment Phase Sequences  
Treatment 
Sequence  Period 1  Period 2  Period 3  Period 4  Period 5  Period 6  
ABFCED  A B F C E D 
BCADFE  B C A D F E 
CDBEAF  C D B E A F 
DECFBA  D E C F B A 
EFDACB  E F D A C B 
FAEBDC  F A E B D C 
Treatment A: Placebo  
Treatment B: Oxycodone 20 mg 
Treatment C: GE-IR 200 mg  + Oxycodone 20 mg 
Treatment D: GE-IR 450 mg  + Oxycodone 20 mg 
Treatment E: GE-IR 200 mg 
Treatment F: GE -IR [ADDRESS_621130] (or delegate ). When all PD assessments during the qualification phase have 
been completed , the randomization will be released to allow for the evaluation of qualification 
criteria. For the treatment phase, the randomization will remain blinded  until all the CRFs  have 
been approved and signed.  
The preparation and/or administration of the product s will be performed by [CONTACT_483292].  
The randomization code must not be broken except in emergency situations where the 
identification of a subject’s study treatment is required by  [CONTACT_483293] a SAE  report. Code break envelopes containing randomization 
information  will be held by [CONTACT_394522](s). The date and reason for breaking the blind 
must be recorded.  
5.2.5.  Study Drug A ccountability  
Complete and accurate inventory records of all study drugs will be kept. This includes 
acknowledgment of receipt of each shipment of study product (quantity and condition), subject 
dispensing records, and returned or destroyed study product.  
Drug accountability will be performed at the completion of the trial.  
Protocol No: AR26.3031.[ADDRESS_621131] Number: ABO -P4-[ADDRESS_621132] 1 hour after 
each drug administration . 
5.3.1.  Treatment Compliance  
The s tudy drug (s) will be dispensed only to eligible subjects and administered under the 
supervision of study personnel. Treatment compliance will be verified according to the site’s 
standard operating procedures ( SOPs ). 
5.4. Other Protocol Restrictions  
Subjects will remain seated or kept in minimal ambulatory movement for at least [ADDRESS_621133]. 
However, should AEs occur at any time, subjects may be placed in an appropriate p osition. 
During this interval subjects will be permitted, under supervision, to get up (e.g. , to use the 
washroom facilities). Subjects will not engage in strenuous activity at any time during the 
confinement periods.  
6. STUDY  PROCEDURE S 
Unless otherwise stat ed in this protocol, the SOPs of the study facilities, which are available for 
all activities relevant to the quality of the study, will be followed during this study.  
An overview of the study activities  for each  subject  is detailed  in Table 1Table 1. 
Pharmacodynamic data collection (vital signs then subjective measures) is to be prioritized, 
followed by [CONTACT_483280], when clinical ac tivities are scheduled to occur at the same time.  
Subjects will be confined to the clinical site from Day -[ADDRESS_621134] dose  of the treatment phase.  
Protocol No: AR26.3031.[ADDRESS_621135] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 38 of 84 
Subjects will be discharged on Day 17 of the treatment phase.  
Any deviation from protocol procedures shall be noted in the source documentation and 
compi[INVESTIGATOR_483256] r eporting in the Clinical Study Report . 
6.1. Safety  Assessments  
Safety asse ssments will include physical examination, C -SSRS, vital signs (i.e.,  systolic and 
diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], oral temperature, SpO 2), continuous SpO [ADDRESS_621136]’s  well-being and history of  relevant  past 
medical events/experiences.  Medical history will in clude all d emographic data (age, gender,  
race, body weight, height, and BMI) and baseline characteristics.  Smoking habits will also be 
recorded.  
Any medical conditions occurring from the time of signing the ICF  through the first dose of 
study treatment in the qualification phase will be recorded as medical history. If the condition 
meets the criteria for an SAE it will be reported as described in s ection 7.6. Medical history 
conditions worsening and judged to be clinically significant will be recorded as AEs.  
6.1.2.  Recreational Alcohol/Drug Use  
A lifetime history of all drug use will be collected as scheduled in  Table 1Table 1. History, 
including drug preference (i.e., drug of choice), frequency of use, and date of last use will be 
collected using reported drug names by [CONTACT_156276] (e.g., cannabinoids, depressants, dissociative 
anesthetics, hallucinogens, opi[INVESTIGATOR_113049], and stimulants). A history of 
alcohol use will als o be collected.  
DSM -IV modules will be included as a part of the recreational drug/alcohol use history and used 
to screen for alcohol and substance dependence.  
6.1.3.  Physical Examination  
A physical examination will be performed by a medically qualified and licen sed individual a s 
scheduled in Table 1Table 1. 
The physical examination will include a general review  of the  following  body system s (at 
minimum) : general appearance, head , eyes, ears, nose  and throat (HEENT) , neck/thyroid, 
cardiovascular , respi[INVESTIGATOR_696] , gastrointestinal , neurological , musculoskeletal/ex tremi ties, and skin . 
A symptom -oriented physical exam may be conducted as indicated in  Table 1Table 1, at the 
discretion of an investigator.  
Protocol No: AR26.3031.[ADDRESS_621137] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 39 of 84 
6.1.4.  Vital Sign s 
Vital signs will be measured as scheduled in  Table 1Table 1 and will include spot blood 
pressure, pulse rate, respi[INVESTIGATOR_14367] (SpO 2) measures.  
All vital signs will be interpreted by [CONTACT_483294], abnormal not cl inically 
significant (NCS), or abnormal clinically significant (CS). New or worsening abnormalities that 
are judged to be clinically significant will be recorded as AEs.  
Vital signs will be measured after being in supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_483257] t 5 minutes.  
[IP_ADDRESS].  Continuous and Spot Oxygen Saturation  
Assessments of respi[INVESTIGATOR_483258] [ADDRESS_621138]’s fingertip. Continuous oxygen saturation will be monitored 
through  a continuous pulse oximeter during the Qualification phase and through  a capnogr aphy 
monitor  during the Treatment phase . 
SpO 2 will be monitored for alarms continuously up to 1 hour prior to each study drug 
administration and will continue for up to 6 hours following each drug administration, or longer 
if deemed medically necessary. An y SpO 2 event that is deemed clinically significant will be 
reported as an AE if it meets the criteria of significance defined in section 6.1.8 . 
[IP_ADDRESS].  Continuous and Spot End -Tidal CO [ADDRESS_621139] dosing, as 
scheduled in Table 1Table 1. Any EtCO 2 event that is deemed clinically significant will be 
reported as an AE if it meets the criteria of significance defined in section 6.1.8 . 
[IP_ADDRESS].  Continuous and Spot Respi[INVESTIGATOR_483259] 1Table 1. Spot respi[INVESTIGATOR_483260] [ADDRESS_621140] dosing, as scheduled in Table 1Table 1. 
Any respir atory rate event that is deemed clinically significant will be reported as an AE if it 
meets the criteria of significance defined in section 6.1.8 . 
Protocol No: AR26.3031.[ADDRESS_621141] Number: ABO -P4-[ADDRESS_621142] panels (not required for subject safety).  
Each abnormal value will be interpreted by [CONTACT_483295], or abnormal CS. 
New or worsening abnormalities that are judged to be clinically significant will be recorded as 
AEs.  
Only test results required by [CONTACT_59077]/or abnormal results will be entered in the clinical 
database and reported in the CSR , based on report requirement s. 
6.1.7.  Columbia Suicide Severity Rating Scale (C -SSRS)  
The C -SSRS is a unique, simple, and short method of assessing both behavior and ideation that 
tracks all suicidal events and provides a summary of s uicidal ideation and behavior. It assesses 
the lethality of attempts and other features of ideation (frequency, duration, controllability, 
reasons for ideation, and deterrents), all of which are significantly predictive of completed 
suicide . 
To monitor for  a history of (the past 2 years/24 months to present) or the emergence during study 
participation of suicidal ideation and behavior, subjects will undergo C -SSRS evaluations at the 
timepoints indicated in Table 1Table 1. 
A trained rater will record the clinical observations on the scale, which will be used as the source 
document. See APPENDIX 7APPENDIX 7  for a sample C -SSRS –Baseline/ Screening version 
assessment  and APPENDIX [ADDRESS_621143] becomes suicidal during the study, an investig ator or medically qualified 
sub-investigator should provide the appropriate treatment  and/or referral to the subject.  
6.1.8.  Assessment of Respi[INVESTIGATOR_483261] f or EtCO 2, SpO 2, and respi[INVESTIGATOR_483262], as defined below:  
Capnography alarms will be set to evaluat e for respi[INVESTIGATOR_2341] , for whichever threshold is 
reached first for a given endpoint,  and will include:  
Protocol No: AR26.3031.[ADDRESS_621144] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 41 of 84 
• An increase in EtCO 2 to >50 mmHg , or an absolute increase  in EtCO 2 of 10 mmHg  
compared to baseline  
• A reduction in SpO 2 to <90% , or an absolute decrease  in SpO 2 of 4%  compared to 
baseline  
• A reduction in respi[INVESTIGATOR_80753] < 8 breaths per minute , or an absolute decrease  in 
respi[INVESTIGATOR_135890] 50%  compared to baseline  
All alarms will be assessed for clinical significance and reporte d as AEs, as applicable. 
Supplemental oxygen will be given as medically necessary.  
6.1.9.  Rescue Therapy  
The clinical study site is equipped with emergency equipment and supplies that correspond with 
the level of risk associated with this study. In case of a medi cal emergency or an SAE requiring 
medical intervention, emergency equipment and supplies will be available and will include, but 
may not be limited to, stocked crash carts, oxygen source, suction pump, and defibrillator. 
Emergency medication (e.g., flumaze nil, diphenhydramine, epi[INVESTIGATOR_238], methylprednisolone, 
ranitidine, rescue medication required for advanced cardiac life support [ACLS]) may be 
administer ed if deemed necessary by [CONTACT_483296]. If required, subjects will be 
transported to a h ospi[INVESTIGATOR_307].  
During the qualification and treatment phases, the principal investigator (PI) or designee will be 
on-site at the time of study treatment administration until at least 6 hours postdose. 
ACLS -certified staff will be present on site and an investigator will be readily available by 
[CONTACT_756].  
When not available on -site, the PI [INVESTIGATOR_113069] -call until the end of the study. While 
confined in the CRU, subjects will be supervised by [CONTACT_113123]/or paramedics. Dedicated 
nurses and/or paramedics will be available to monitor AEs and perform safety measures.  
The date and time of rescue medication administration , as well as the name [CONTACT_483314] , will be recorded.  
6.2. Blood Volume  Collected  
The total blood volume for screening and safety assessments will be approximately 15 mL. 
Blood volume required for pharmacokinetic assessments will be included in the informed 
consent.  
6.3. Pharmacokinetic Assessments  
Blood samples will be collected for each do se in the treatment phase  for PK assessments  of 
gabapentin and oxycodone . The complete blood sampling schedule is presented in  Table 4Table 
4. 
Protocol No: AR26.3031.[ADDRESS_621145] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 42 of 84 
Table 4. Pharmacokinetic Blood Sampling Schedule  (Gabapentin and Oxycodone)  
Sample No  Nominal  Time * 
(hours)  
01 0.0 
02 0.5 
03 1 
04 1.5 
05 2 
06 2.5 
07 3 
08 4 
09 5 
10 6 
11 7 
12 8 
13 10 
14 24 
* Nominal times listed are relative to the time of study treatment administration.  
Blood samples will be collected by [CONTACT_230491] a labeled tube containing the 
appropriate anticoagulant as specified by [CONTACT_85332]. As an option to the subject , or 
if judged necessary by [CONTACT_49885], blood samples may be collected using a catheter that  
will be placed in the vein of the subject.  
The time of PK blood sample collection will be calculated relative  to the time of treatment 
administration. The actual time of all PK blood draws will be recorded and reported for all 
subjects.  Each subject will be dosed at approximately the same time in each period and all 
activities (e.g.,  PK sampling, scales, meals) will be based on that dosing time.  
Urine samples to be collected duri ng the course of this study include pregnancy tests and drug 
screens as outlined in Table 1Table 1. 
Gabapentin and oxycodone concentrations for PK assessmen ts will be obtained through 
bioanalysis of the plasma derived from the blood samples drawn during this study , using 
validated bioanalytical method s. 
6.3.1.  Pharmacokinetic Sample Processing, Storage and S hippi[INVESTIGATOR_483263], stored, and shipped according to the 
sample processing instructions supplied by [CONTACT_85332].  Each tube will be 
appropriately labeled  (e.g., analyte, sample collection time, subject identifier) . 
Protocol No: AR26.3031.[ADDRESS_621146] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 43 of 84 
6.4. Pharmac odynamic Assessments  
Pharmacodynamic assessments will be performed throughout the study as outlined in Table 
1Table 1. 
Prior to completing the computerized P D measures, all subjects will undergo a scripted training 
and practice session . Eligible subjects experiencing  difficulty differentiating between bipolar and 
unipolar VAS (e.g., making errors such as selecting 50  as ‘neutral ’ for a unipolar scale) or 
difficulty distinguishing between "at this moment" and "next -day" measures during the 
qualification phase will undergo additional practice training on the difference between the scale 
types. Additional training sessions will be do cumented in source files.  
Testing conditions for PD assessments should remain as consistent as possible across the study 
(i.e., qualification and treatment phases) . Subjects will be monitored carefully to ensure that they 
are completing the PD assessments appropriately; all reasonable attempts should be made to 
rouse subjects who fall asleep during testing cycles. If subjects cannot complete the PD 
assessments in a timely manner prior to the next required procedure or timepoint due to an AE, 
testing may be aborted and the reason for discontinuation of a PD assessment will be provided . 
6.4.1.  Subjective Effects  
[IP_ADDRESS].  Visual Analogue Scales  
All VAS will be scored on a [ADDRESS_621147] being measured. Bipolar scales ask about the neutrality, the 
direction, and the intensity of a subjective opi[INVESTIGATOR_1649], whereas unipolar scales only ask about the 
extremity or intensity of a subjective opi[INVESTIGATOR_1649]. When VASs are administered as bipolar scales, a 
neutral point equal to 50 is embedded within the scale (e.g., Drug Liking, Ove rall Drug Liking, 
Take Drug Again, Drowsiness/ Alertness VAS). The neutral point reflects a state whereby a 
subject is experiencing neither negative nor positive effects (e.g., neither dislike nor like the 
effects of the drug) and is labeled with an anchor , such as “neither like nor dislike.”  When VASs 
are administered as unipolar scales, anchors will be presented using text such as “Not at all” 
(score = 0) to “Extremely” (score = 100; e.g., Good, Bad, High, and Any Effects VASs). 
Unipolar scales do not in clude a neutral point but rather, a rating of “0” reflects the complete 
absence of a subjective effect while a rating of “100” reflects the maximum presence of a 
subjective effect (e.g., No Good Effects = 0, Extremely Good Effects = 100). Scales that refer  
specifically to drug (e.g., Drug Liking, Good Effects VAS, Bad Effects VAS, and Any Effects 
VAS) are not administered  at predose.  
Protocol No: AR26.3031.[ADDRESS_621148] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 44 of 84 
Table 5. Visual Analog Scale (VAS) Descriptions  
Scale 
Interpretation  Include 
Predose  Type of 
Scale  Description  Question Text  Response Anchors  
Balance  No Bipolar  Drug Liking  At this moment, my liking 
for this drug is  0: Strong disliking  
50: Neither like nor 
dislike  
100: Strong liking  Balance  No Bipolar  Overall Drug Liking  Overall, my liking for this 
drug is  
Balance  No Bipolar  Take Drug Again  I would take this drug again  0: Definitely would 
not 
50: Neither would 
nor would not  
100: Definitely 
would  
Positive  No Unipolar  Good Effects  At this moment, I feel good 
drug effects  
0: Not at all  
100: Extremely  Positive  Yes Unipolar  High  At this moment, I am feeling 
high 
Negative  No Unipolar  Bad Effects  At this moment, I feel bad 
drug effects  
Other  No Unipolar  Any Effects  At this moment, I can feel 
any drug effect  
Other  Yes Unipolar  Feeling Drunk  At this moment, I am feeling 
drunk  
Other  Yes Bipolar  Drowsiness/Alertness  At this moment, my mental 
state is  0: Very drowsy  
50: Neither drowsy 
nor alert  
100: Very alert  
Other  Yes Bipolar  Relaxation/Agitation  At this moment, my mental 
state is  0: Very relaxed  
50: Neither relaxed  
nor agitated  
100: Very agitated  
 
Protocol No: AR26.3031.[ADDRESS_621149] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 45 of 84 
[IP_ADDRESS].  Addiction Research Center Inventory (ARCI)  
Martin et al. [ADDRESS_621150]  compi[INVESTIGATOR_42602] a shortened version (49 true -false items) from the 550 -item 
Addiction Research Center Inventory (ARCI) originally developed by [CONTACT_186508] .36,37 This version 
of the shortened ARCI contains 5 scales, which measure the following effects:  
• Euphoria: Morphine -Benzedrine Group (MBG) scale  
• Stimulant effects: Amphetamine (A) scale, Benzedrine Group (BG) scale  
• Dysphoria: Lysergic Acid Diethylamide (LSD) scale  
• Sedation: Pentobarbital -Chlorpromazine -Alcohol Group (PCAG) scale  
The ARCI MBG and PCAG scales will be administered as scheduled in  Table 1Table 1. The 
ARCI MBG and PCAG scales  are presented in APPENDIX 9APPENDIX 9  and APPENDIX 
10APPENDIX 10 , respectively.  
6.4.2.  Modified Observer’s Assessment of Alertness/Sedation (MOAA/S)  
The MOAA/S is an observer -rated measure of alertness/sedation that is used widely in clinical 
research. It is based on the following 6 items, rated on a scale from 5 (not sedated) to 
0 (unarousable):  
The Observer’s Assessment of Alertness/Sedation Scale (OAA/S) was developed to measure the 
level of alertness in subjects who are sedated.34 The OAA/S is a reliable validated measure and 
was shown to be sensitive to different levels of sedation and is composed of 4 assessment 
categories that include responsiveness, speech, facial e xpression, and eyes. The Modified 
Observer's Assessment of Alertness/Sedation Scale (MOAA/S) includes only the Responsiveness 
assessment category. It is easy and quick to administer (less than 1 minute). The subjects’ level 
of responsiveness is measured in  a 5-point Likert scale:  
Responsiveness  Score  
Responds readily to name [CONTACT_154992]  5 (Alert)  
Lethargic response to name [CONTACT_154992]  4 
Responds only after name [CONTACT_248794]/or repeatedly  3 
Responds only after mild prodding or shaking  2 
Does not respond to mild prodding or shaking  1 (Deep Sleep)  
7. ADVERSE EVENTS DOCUMENTATION  
7.1. Definitions  
An AE is defined as any untoward medical occurrence in a subject administered an 
investigational product and which does not necessarily have a causal relationship with the 
treatment. An AE can therefore be any unfavorable and unintended sign (including a clinic ally 
significant abnormal clinical laboratory finding, for example), symptom, or disease temporally 
associated with the use of an investigational product, whether or not related to the investigational 
product.  
Protocol No: AR26.3031.[ADDRESS_621151] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 46 of 84 
A suspected adverse reaction (SAR) is any AE for which there is a reasonable possibility the 
drug caused the AE. ‘Reasonable possibility’ means there is evidence to suggest a causal 
relationship between the drug and the AE. A suspected adverse reaction implies a lesser degree 
of certainty about causality than adverse reaction, which means any AE caused by a drug.  
Regarding marketed medicinal products, an adverse drug reaction is defined as a response to a 
drug which is noxious and unintended and which occurs at doses normally use d in man for 
prophylaxis, diagnosis, or therapy of disease or for modification of physiological function.  
An AE may be:  
• A new illness,  
• Worsening of a concomitant illness,  or 
• An effect of the study drug including comparator; it could be an abnormal clinical  
laboratory value as well as a significant shift from baseline within normal range which an 
investigator  considers to be clinically important.  
Surgical procedures themselves are not AEs. They are therapeutic measures for conditions that 
required surgery. T he condition for which the surgery is required is an AE, if it occurs or is 
detected during the study period. Planned surgical measures permitted by [CONTACT_154575](s) leading to these measures are not AEs, if the condition(s ) was 
(were) known before the start of study treatment. In the latter case, the condition should be 
reported as medical history.  
An SAE  or reaction is any untoward medical occurrence that at any dose:  
• Results in death,  
• Is life -threatening,  
• Requires inpatie nt hospi[INVESTIGATOR_1081],  
• Results in persistent or significant disability or incapacity (defined as a substantial 
disruption of a person’s ability to conduct normal life functions),  
• Is a congenital anomaly or birth def ect, or 
• Is an important medical event (including development of drug dependence or drug abuse) 
that may jeopardize the subject or may require intervention to prevent  one of the other 
outcomes listed above (according to medical judgment of an investigator) . 
7.2. Severity Assessment  
All AEs will be graded as mild, moderate, or severe according to the following definitions:  
Mild : Causing no limitation of usual activities; the subject may experience transient slight 
discomfort . 
Moderate : Causing some limitation of usual activities; the subject may experience annoying 
discomfort . 
Protocol No: AR26.3031.[ADDRESS_621152] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 47 of 84 
Severe : Causing inability to carry out usual activities; the subject may experience intolerable 
discomfort or pain . 
Every effort will be made to obtain an adequate evaluation o f the severity.  
7.3. Causality Assessment  
An investigator will determine the relationship of any AE to the study drug using the guidelines  
presented  in Table 6Table 6. 
Table 6. Adverse Event Relationship to Study Drug  
Relationship to Drug  Comment  
Reasonable Possibility  A temporal relationship exists between the adverse event ( AE) onset 
and administration of the investigational product that cannot be readily 
explained by [CONTACT_423]’s clinical state or concomitant therapi[INVESTIGATOR_014].  
Furthermore, the AE appears with some degree of  certainty to be 
related, based on the known therapeutic and pharmacologic actions or 
AE profile of the investigational product.  
In case of cessation or reduction of the dose the AE may abate or 
resolve and it may reappear upon rechallenge.  
No Reasonable Possibility  Evidence exists that the AE has an etiology other than the 
investigational product.  
For serious adverse events ( SAEs ), an alternative causality must be 
provided (e .g., pre existing condition, underlying disease, intercurrent 
illness, or concomitant medication).  
 
7.4. Adverse Event Monitoring  
For the purposes of this study, the monitoring period for AEs extends from the time of first study 
treatment administration in the qualification phase  until the follow -up visit . If AEs are ongoing 
after t he follow -up visit, attempts will be made to follow the AEs to resolution. Any medical 
conditions occurring from the time of signing the ICF  through the first dose of study treatment in 
the qualification phase will be recorded as medical history. If the co ndition meets the criteria for 
an SAE it will be reported as described in section 7.6. 
Subjects will be questioned on their health status prior to each study treatment and periodically 
thereafter, including prior to PD measurements. Open -ended questions will be asked.  
During the study, all AEs spontaneously reported by [CONTACT_423], observed by [CONTACT_483297] l be recorded for all subjects and reported in the CRF.  
Every  effort will be made to obtain an adequate follow -up of the subjects  and the final outcome . 
Should any subject choose to withdraw from the study, they will be advised of the safety 
precautions to be taken.  
Protocol No: AR26.3031.[ADDRESS_621153] Number: ABO -P4-[ADDRESS_621154] visit will require an  appropriate  evaluation and 
follow -up until the AE has been resolved  or a reasonable explanation for its persistence is found, 
or it is deemed mild and safely reso lving.  
It is an investigator’s responsibility to ensure subjects experiencing adverse events receive 
appropriate follow -up, treatment where required, and that every action is well documented.  
Classification of AEs will be performed by [CONTACT_9313] (S OC) and preferred t erm (PT) 
using the Medical Dictionary for Regulatory Activities (MedDRA), version 23.0 or higher.  
Concomitant medications will be cod ed using the World Health Organiz ation Drug D ictionary -
Enhanced  (WHO -DDE March 2019 or later ). 
7.5. Reporting of Pregnancy  
Pregnancy in a female study subject  shall be reported to the sponsor within 24 hours of the 
knowledge of its occurrence by [CONTACT_483298]  (for pregnancies occurring during the 
course of the study or up to 30 days  followi ng the end of the study). Because of the possibility 
the fetus/embryo could have been exposed to the study drug through the parent and for the 
subject’s safety, the pregnancy will be followed up to determine its outcome, including 
spontaneous or voluntary termination, details of birth, presence or absence of any birth defects, 
congenital anomalies, or maternal and/or newborn complications.  
The pregnancy will be recorded and reported by [CONTACT_483299]. Pregnancy 
follow -up will also be prope rly recorded to ensure quality and completeness of the data 
belonging to the study drug and will include an assessment of the possible causal relation 
between the study drug and any pregnancy outcome. Any SAE experienced during pregnancy 
will be reported o n an SAE Report Form.  
7.6. Serious Adverse Event Reporting  
The CRU  will notify any SAE to the sponsor  or designee , without regard to causality, within 
[ADDRESS_621155](s). Information not available at the time of the initial report (e.g. , an end date for the AE, 
laboratory values received after the report, or hospi[INVESTIGATOR_44458]) must be documented. 
All follow -up information must be reported as  soon as the relevant info is available , in the same 
manner as the initial report . 
If an SAE occurs to a subject during this study, the SAE report and relevant medical records 
should be faxed at the time of the report to Arbor Safety Inbox at (470) 235 -2400 or scanned and 
emailed to [EMAIL_9294] . The SAE may also be reported by [CONTACT_483300] (866) 516 -4950 . 
An SAE will be consider ed “unexpected” if the AE is not listed in the US product inserts 
(USPIs)  or is not listed at the specificity or severity that has been observed; or, if an investigator 
Protocol No: AR26.3031.[ADDRESS_621156] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 49 of 84 
brochure is not required or available, is not consistent with the risk information desc ribed in the 
general investigational plan or elsewhere in the current application. "Unexpected," as used in this 
definition, also refers to AEs that are mentioned in the USPIs  as occurring with a class of drugs 
or as anticipated from the pharmacological pr operties of the drug but  are not specifically 
mentioned as occurring with the particular drug under investigation.  
The CRU  will determine whether any serious , unexpected , related AE must be reported to the 
institutional review b oard ( IRB). If so, the even t will be repo rted via fax or email within 
[ADDRESS_621157] be reported in an expedited manner to the 
applicable regulatory agencies. If so, the sponso r will report the event to those agencies and to all 
participating investigators.  
If reports of any new and unexpected AEs become available to the sponsor during the clinical 
portion of this study, the sponsor or designee will  advise the CRU, through its clinical 
investigator, of those events. If required, the sponsor will report to the applicable regulatory 
authorities.  
8. DATA ANALYSIS  AND STATISTICAL METHODS  
8.1. Analysis Populations  
8.1.1.  Qualification Phase  
[IP_ADDRESS].  Qualification Randomized Population  
The Qualification Randomized population will include all subjects who are assigned a 
randomization number in the qualification phase.  
[IP_ADDRESS].  Qualification Safety Population  
The Qualification Safety population will include all subjects who ar e randomized into the 
qualification phase and receive at least 1 dose of either placebo  or oxycodone . 
8.1.2.  Treatment Phase  
[IP_ADDRESS].  Randomized Population  
The Randomized p opulation will include all subjects who are assigned a randomization number 
in the treatment phase.  
[IP_ADDRESS].  Safety Population  
The Safety  population will include all subjects in the Randomized p opulation who receive at 
least 1 dose of study drug (e.g. placebo, oxycodone or GE -IR). 
[IP_ADDRESS].  Completer Population  
All subjects in the Safety population who complete all [ADDRESS_621158] sufficient data for evaluation of the primary endpoint (based on a blinded 
review of data prior to database lock) will be included in the Completer population. Subjects who 
do not have at least 1 o bservation within 2 hours of T max for each treatment for Drug Liking VAS 
will be excluded from the Completer population.  
Protocol No: AR26.3031.[ADDRESS_621159] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 50 of 84 
[IP_ADDRESS].  Modified Completer Population  
All subjects in the Completer population excluding problematic subjects with unreliable 
responses which can alter study results. For the Drug Liking VAS scale, the following 
elimination criteria will be used to define the Modified Completer population.  
a) Similar E max scores (within a 5 -point difference) for a subject across all study treatments 
(including placebo)  
OR 
b) Emax for placebo > 60 AND the E max(placebo) – Emax(positive control) ≥ [ADDRESS_621160] in the stud y, then the Modified Completer  populatio n is the same as 
the Completer p opulation.  
[IP_ADDRESS].  Pharmacokinetic (PK) Population  
The PK p opulation will incl ude all subjects in the Safety p opulation who receive at least [ADDRESS_621161] no p rotocol deviations or 
other circumstances that would exclude them from analysis.  
8.2. Appropriateness of Measures  
The selected PD measures will assess positive and negative subjective drug effects associated 
with the abuse potential of a drug. These subjective measures are consistent with guidelines for 
HAP  studies4 and are similar to those used in previous studies. Although data from all measures 
will be considered in the assessment of abuse potential, the Drug Liking VAS has been selected 
as the primary endpoint for practical purposes (such as calculating power and assessing 
qualification eligi bility), as it is considered [ADDRESS_621162]’s global assessment of the drug and have 
face validity for predictin g continued use of a drug. High V AS has also been selected as a key 
secondary endpoint because it has been shown to be sensitive in capturing the positive subjective 
effects of test drugs. Additional secondary endpoints assess other subjective effects of t he drug 
that may help w ith interpretation of the data.  
Standard PK parameters will be evaluated to confirm plasma concentrations and the PK profile 
of GE-IR in nondependent , recreational drug users. Standard measures of safety will be included 
to monitor t he safety and tolerability of the GE-IR doses used in the study.  
8.3. Missing Values  
No imputation of missing PD or PK data will be performed.  
The occurrence of missing PD data will be minimized by [CONTACT_483301]. In addition, all reasonable 
attempts will be made to rouse subjects for completion of the PD assessments in both the 
qualification and treatment phases. Missing PD data, including reasons for the missing data, will 
be list ed by [CONTACT_1130], and examined on a case -by-case basis to determine if these affect subject 
allocation (i.e., inclusion in the Modified Completer population/Completer population, as 
Protocol No: AR26.3031.[ADDRESS_621163] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 51 of 84 
appropriate). If for a given PD measure, the predose value is missing, calcul ation of CFB min and 
TA_AOE will not be possible, and the subject will not be included in the Modified Completer 
population/Completer population (as appropriate) for that PD endpoint. If the actual date and/or 
time of a postdose PD assessment is unknown, bu t there is a result at that timepoint, the value 
will be used in descriptive statistics of treatment by [CONTACT_483302], and PD endpoint by 
[CONTACT_483303]_AUE and TA_AOE which 
need actual time from dose in order to be calculated.  
If the actual collection time of a postdose PK sample is unknown, but a valid concentration value 
has been measured, the sample will be set to missing in the PK analysis and will be presented in 
listing but excluded from descript ive statistics. Unknown baseline collection times will be 
handled on a case -by-case basis.  
Further details on handling of missing values will be provided in the Subject Allocation and 
Request to Break the Blind Form, and in the Statistical Analysis Plan (S AP). 
8.4. Demographic Data and Other Baseline Characteristics  
8.4.1.  Qualification Phase  
All subjects who are randomized into the qualification phase will be entered into the database. 
Disposition tables and listings will be presented for all subjects in the qualification phase, and for 
qualification failures. Tables for demographic and baseline characteristics (sex, age, race, 
ethnicity, body weight, height, BMI) will be presented by [CONTACT_66067], and by [CONTACT_483304]. Demographics and baseline charact eristics for subjects who pass and who fail the 
qualification phase will be listed.  
8.4.2.  Treatment Phase  
A disposition table will be presented for subjects randomized to the treatment phase. 
Demographics and baseline characteristics (sex, age, race, ethnicity, body weight, height, BMI), 
recreational drug use history, alcohol use history, and smoking history will be summarized using 
descriptive statistics (n, mean, SD, minimum, median, and maximum for continuous variables, 
and the proportion of subjects for categ orical variables) for the Safety population. No formal 
statistical comparison between the groups will be performed.  
Medical history will be listed by [CONTACT_1130]. Medical history will be coded into the most recent 
version of MedDRA available (version 23.0 or l ater).  
Prior and concomitant medications will be assigned a [ADDRESS_621164] assessment will be listed.  
Protocol No: AR26.3031.[ADDRESS_621165] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 52 of 84 
8.5. Pharmacodynamics  
8.5.1.  Pharmacodynamic Endpoints  
Pharmacodynamic  endpoints will be evaluated as described in Table 7Table 7 and PD data will 
be analyzed for the Modified Completer population . During the treatment phase, PD values at 
each timepoint will be summarized by [CONTACT_483305]. Derived endpoints will be summarized using descriptive statistics.  
Table 7. Pharmacodynamic Endpoints  
Description  Type  Endpoints  
Drug Liking  Balance of effects, Bipolar V AS  Emax, Emin, TE max, TE min, and 
TA_AUE  
Overall Drug Liking  Global effects, Bipolar V AS  Emax 
Take Drug Again  Global effects, Bipolar V AS  Emax 
Good Effects  Positive effects, Unipolar V AS  Emax, TE max, and TA_AUE  
High  Positive effects, Unipolar V AS  Emax, TE max, and TA_AUE  
Bad Effects  Negative effects, Unipolar V AS  Emax, TE max, and TA_AUE  
Any Effects  Other effects, Unipolar V AS  Emax, TE max, and TA_AUE  
Feeling Drunk  Other effects, Unipolar V AS  Emax, TE max, and TA_AUE  
Drowsiness/Alertness  Other effects, Bipolar V AS  Emin, TE min, and TA_AUE  
Relaxation/Agitation  Other effects, Bipolar V AS  Emin, TE min, and TA_AUE  
Addiction Research Center Inventory 
(ARCI) Morphine -Benzedrine Group 
(MBG) Scale  Positive, euphoric effects, 
Questionnaire score  Emax, TE max, and TA_AUE  
ARCI Pentobarbital –
Chlorpromazine –Alcohol Group 
(PCAG) Scale  Other, sedative effects, 
Questionnaire score  Emax, TE max, and TA_AUE  
Modified Observer’s Assessment of 
Alertness/Sedation (MOAA/S)  Other, sedative effects, Observer’s 
score  Emin, CFB min, and TA_AUE  
TA_AUE=time -averaged area under the effect -time curve, CFB min= change from baseline to minimum effect,  Emax= 
maximum (peak) effect, Emin=minimum effect , TE max=time of maximum (peak) effect , TE min=time of minimum 
effect  
8.5.2.  Pharmacodynamic Statistical Methodology  
Drug Liking VAS E max from the qualification phase will be summarized by [CONTACT_483306].  The data will be evaluated to confirm that an 
appropriate population was selected for the treatment phase.  
During the treatment phase, PD values at each timepoint will be summarized by [CONTACT_186492]. Derived endpoints will be summarized by 
[CONTACT_186493].  
Protocol No: AR26.3031.[ADDRESS_621166] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 53 of 84 
[IP_ADDRESS].  Primary Analysis  
Pharmacodynamic endpoints for the treatment phase ( Emax, Emin, CFB min, TA_AUE and 
TA_AOE , as appropriate) will be analyzed using a mixed -effect model if the residuals are 
normal ly distributed . The model will include treatment, period, treatment sequence, and 
first-order carryover effect (where applicable) as fixed effects, and the baseline (predose) 
measurement as a covariate (where applicable). If the variance among treatments is 
homogeneous, subject will be considered a random effect; if the variance among treatments is 
heterogeneous, the default variance components (VC) variance structure block will be used for 
each subject. Treatments for each PD endpoint will be tested for homogeneity of variance using 
the SAS procedure PROC GLIMMIX COVTEST. If treatments for a given PD endpoint are 
homogeneous, the option “RANDOM SUBJECT;” will be used in the PROC MIXED model. If 
treatments for a give PD endpoint are heterogeneous, the option 
“REPEATED/SUBJECT=SUBJECT GROU P=TREATMENT;” will be used in addition to the 
option “RANDOM SUBJECT;” in the PROC MIXED model.  
After it is determined if the treatment variance is homogeneous or heterogeneous, the residuals 
from each mixed -effect model will be investigated for normality using the Shapi[INVESTIGATOR_2152] -Wilk W test.  
The null and alternative hypotheses for this analysis are shown below:  
H0: distribution of residuals is normal vs. H a: distribution of residuals is not normal  
If the residuals from the mixed -effect model are normall y distributed, e.g., p -value ≥ 0.05, it will 
be determined if carryover effects should be included.  
When conducting drug abuse potential studies, Chen and Tsong  [ADDRESS_621167] is found to be non -significant at alpha ≥ 0.25, then th e term 
will be dropped from the mixed -effects model. If the carryover effect is found to be significant at 
alpha < 0.25, it will be included in the model.  
If the normality assumption of the model is satisfied, least -square means, standard errors (SEs), 
and 1-sided 95% or 2 -sided 95% or 90% confidence intervals (CIs) for treatments and treatment 
differences will be derived from the mixed -effect model. P -values will be provided for the effects 
and the contrasts.  
If the normality assumption of the model is not  satisfied, the distribution of the paired difference 
for each contrast  will be examined in terms of normality and skewness. Each paired difference 
will be investigated for normality using the Shapi[INVESTIGATOR_2152] -Wilk W -test. If the p -value for the 
distribution of the  paired difference is normal, that is, p -value ≥ 0.05, a paired t -test will be used.  
Protocol No: AR26.3031.[ADDRESS_621168] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 54 of 84 
If the paired difference is not normally distributed, that is, p -value < 0.05, the following steps 
will be taken to test skewness:  
a) If the alternative hypothesis is upper -tailed, and skewness is [0, 0.5] then mean 
difference, SE, 1 -sided 95% CI, and p -value from the t -test will be output.  
b) If the alternative hypothesis is upper -tailed, and skewness < 0 or skewness > 0.5 then 
median of the paired difference (Q1 -Q3), 1 -sided 95 % CI, and p -value from the sign 
test will be output.  
c) If the alternative hypothesis is lower -tailed, and skewness is [ -0.5, 0] then mean 
difference, SE, 1 -sided 95% CI, and p -value from the t -test will be output.  
d) If the alternative hypothesis is lower -tailed, and skewness < -0.5 or skewness > 0 then 
median of the paired difference (Q1 -Q3), 1 -sided 95% CI, and p -value from the sign 
test will be output.  
e) If the alternative hypothesis is two -tailed, and skewness is [ -0.5, 0.5] then mean 
difference, SE, 2 -sided 9 5% (Hypotheses 1, 2 and 3) or 2 -sided 90% CI (Hypothesis 
4), and p -value from the t -test will be output.  
f) If the alternative hypothesis is two -tailed, and skewness < -0.5 or skewness > 0.5 then 
median of the paired difference (Q1 -Q3), 2 -sided 95% (Hypothese s 1, 2 and 3) or 2 -
sided 90% CI (Hypothesis 4), and p -value from the sign test will be output.  
The calculation of the sign test, and the confidence interval for the median based on the sign test 
will exclude subjects who have zero difference in scores betw een the [ADDRESS_621169] drug in humans.4 The statistical analysis of a HAP study should address the following 
questions:  
1. Does the known drug of abuse (positive control) produce reliable abuse -related responses 
compared to placebo (study validity)?  
2. Does the combination of the test drug and the positive comparator produce abuse -related 
responses that are larger than those of the positive control?  
3. Does the test drug produce abuse -related res ponses that are smaller than those of the 
positive control?  
4. Does the test drug produce abuse -related responses that are similar to placebo?  
The objective of this study to assess the relationship between oxycodone and the combination of 
GE-IR and oxycodone therefore Questions 3 and 4 will not be addressed in this study.  
Protocol No: AR26.3031.[ADDRESS_621170] Number: ABO -P4-[ADDRESS_621171] of  the sensitivity and integrity of the study: Does the positive control (C) 
produce mean responses that show greater abuse potential compared to placebo (P)? This 
question may be expressed using the following hypothesis:  
Ho: μC - μP ≤ δ 1 vs. H a: μC - μP > δ 1 where δ 1 > 0 (Hypothesis 1)  
2. Does the combination drug (COMBO) produce mean responses that show more abuse 
potential compared to the positive control (C)?  
Ho: μCOMBO  – μC ≥ δ 2 vs. H a: μCOMBO  – μC < δ 2 where δ 2 = 0.xx( μC ― μP  (Hypothesis 2)  
These hypotheses will be applied to the primary endpoint, Drug Liking VAS E max. For Drug 
Liking V AS E max at a significance level of 0.05; 1 -sided 95% confidence intervals will be 
presented for both hypotheses. For Hypothesis 2, a 2 -sided 95% confidence interval will also be 
provided; it will provide information about the absolute difference between the combination and 
20 mg dose of oxycodone.  
For study validity purposes, the primary endpoint, E max for Drug Liking VAS, will be compared 
between the positive control ( oxycodone 20 mg ) and placebo. The comparison will assess the 
null hypothesis that the mean difference in Drug Liking E max between oxycodone  and placebo is 
less than or equal to [ADDRESS_621172] the alternative hypothesis that the mean difference in Drug Liking 
Emax between oxycodone  and placebo is greater than 15. If statistically significant, it will  confirm 
the sensitivity of the study and allow for the comparison of the other pairwise comparisons 
shown below. The hypotheses can be expressed as follows:  
Ho: μC - μP ≤ 15 vs. H a: μC - μP > 15 (Hypothesis 1)  
where μ C is the mean for the positive contro l, oxycodone , and μ P is the mean for placebo. This 
hypothesis will be applied to the following contrast:  
• Treatment B: Oxycodone 20 mg  vs. Treatment A: Placebo  
Although a margin of [ADDRESS_621173] -hoc analysis will be performed (refer to Section [IP_ADDRESS] ). Hypothesis 2 with 
0.xx= 0.[ADDRESS_621174] -hoc analysis. Further details will be described in the SAP.  
To assess whether the combination drug has more abuse potential than the positive control, t he 
null hypothesis will be that the mean difference in Drug Liking E max betwe en GE -IR + 
oxycodone and oxycodone is greater than or equal to 0.xx(mean difference of positive control vs. 
placebo) against the alternative hypothesis that the mean difference in Drug Liking E max between 
Protocol No: AR26.3031.[ADDRESS_621175] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 56 of 84 
GE-IR + oxycodone and oxycodone is less than or equal to 0.xx(mean difference of positive 
control vs. placebo).  
Comparison between the combination and the positive control, will be:  
Ho: μCOMBO  – μC ≥ δ 2 vs. H a: μCOMBO  – μC < δ 2 where δ 2 = 0.xx( μC ― μP) 
The value of 0.xx is defined as 0.2. The [ADDRESS_621176] result is significant for 0.xx = 0.2 then 
testing of the null hypothesis will continue with 0.xx values decreasing by 
[CONTACT_122271] 0.05 until  a non -significant result is obtained . (Hypothesis 2)  
where μ COMBO  is the mean for the combination of GE -IR + the positive control, μ C is the mean 
for the positive control, oxycodone , and μ P is the mean for placebo . This hypothesis will be 
applied to the following contrasts:  
• Treatment C: GE -IR 200 mg + Oxycodone 20 mg vs. Treatment B: Oxycodone 20 mg  
• Treatment D: GE -IR 450 mg + Oxycodone 20 mg vs. Treatment B: Oxycodone [ADDRESS_621177] Hypotheses for Key Secondary Endpoints  
The key secondary endpoints in this study will be E max of Overall Drug Liking, Take Drug Again 
and High. For the comparisons of key secondary PD endpoints,  the following hypotheses will be 
used: 
Hypothesis 1: Ho: μC − μ P ≤ 0 vs. H a: μC − μ P > 0 
Hypothesis 2: H o: μCOMBO  – μC ≥ δ 2 vs. H a: μCOMBO  – μC < δ 2 where δ 2 = 0.xx( μC ― μP) 
The hypothesis for comparison between the positive control, oxycodone  and placebo will be:  
Ho: μC − μ P ≤ 0 vs. H a: μC − μ P > 0 (Hypothesis 1)  
where μ C is the mean for the positive control, oxycodone , and μ P is the mean for placebo. This 
hypothesis will be applied to the following contrast:  
• Treatment B: Oxycodone 20 mg  vs. Treatment A: Placebo  
The hypothesis for c omparison between the combination and the positive control, will be:  
Ho: μCOMBO  – μC ≥ δ 2 vs. H a: μCOMBO  – μC < δ 2 where δ 2 = 0.xx( μC ― μP) 
The value of 0.xx is defined as 0.2. The [ADDRESS_621178] result is significant for 0.xx = 0.2 then 
testing of the null hypothesis will continue with 0.xx values decreasing by 
[CONTACT_122271] 0.05 until  a non -significant result is obtained . (Hypothesis 2)  
Protocol No: AR26.3031.[ADDRESS_621179] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 57 of 84 
where μ COMBO  is the mean for the combination of GE -IR + the positive control, μ C is the mean 
for the positive control, oxycodone , and μ P is the mean for placebo . This hypothesis will be 
applied to the following contrasts:  
• Treatment C: GE -IR 200 mg + Oxycodone 20 mg vs. Treatment B: Oxycodone 20 mg  
• Treatment D: GE -IR 450 mg + Oxycodone 20 mg vs. Treatment B: Oxycodone 20 mg  
A significance level of 0.05 will be used for all 1 -sided tests; 1 -sided 95% confidence intervals 
will be presented. For Hypothesis 2, a 2 -sided 95% confidence interval will also be provided; it 
will provide information about the absolute difference between the combinat ion and [ADDRESS_621180] Hypotheses for Non -Key Secondary Endpoints  
For the comparisons of all other non -key secondary PD endpoints,  the following hypotheses will 
be used: 
Hypothesis 1 : Ho: μC − μ P = 0 vs. H a: μC − μ P ≠ 0 
Hypothesis 2: H o: μCOMBO  – μC = δ 2 vs. H a: μCOMBO  – μC ≠ δ 2 where δ 2 = 0.xx( μC ― μP) 
The hypothesis for comparison between the positive control, oxycodone  and placebo will be:  
Ho: μC − μ P = 0 vs. H a: μC − μ P ≠ 0 (Hypothesis 1)  
where μ C is the mean for the positive control, oxycodone , and μ P is the mean for placebo. This 
hypothesis will be applied to the following contrast:  
• Treatment B: Oxycodone 20 mg  vs. Treatment A: Placebo  
The hypothesis for c omparison between the combination and the positive control, will be:  
Ho: μCOMBO  – μC = δ 2 vs. H a: μCOMBO  – μC ≠ δ 2 where δ 2 = 0.xx( μC ― μP) 
The value of 0.xx is defined as 0.2. The [ADDRESS_621181] result is significant for 0.xx = 0.2 then 
testing of the null hypothesis will continue with  0.xx values decreasing by 
[CONTACT_122271] 0.05 until a non -significant result is obtained . (Hypothesis 2)  
where μ COMBO  is the mean for the combination of GE -IR + the positive control, μ C is the mean 
for the positive control, oxycodone , and μ P is the mean for placebo . This hypothesis will be 
applied to the following contrasts:  
Protocol No: AR26.3031.[ADDRESS_621182] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 58 of 84 
• Treatment C: GE -IR 200 mg + Oxycodone 20 mg vs. Treatment B: Oxycodone 20 mg  
• Treatment D: GE -IR 450 mg + Oxycodone  20 mg vs. Treatment B: Oxycodone 20 mg  
A significance level of 0.05 will be used for Hypotheses 1  and 2 . For Hypotheses 1  and 2, 
2-sided 95% confidence intervals will be presented . No adjustments for p -values will be made to 
account for multiple comparisons.  
[IP_ADDRESS].  Post-Hoc Analysis  
Although a margin of [ADDRESS_621183] lower responses with oxycodone and higher 
responses with placebo in the treatment phase as compared to the qualification phase ,21,33 
particularly for lower abuse potential drugs such as benzodiazepi[INVESTIGATOR_1651] (i.e.,  Schedule IV drugs). 
Therefore, in the case that the difference between the active control and placebo do not meet the 
pre-specified criteria for validity of at least 15, exploratory analysis will be performed.  Details of 
the post -hoc analysis will be described in the SAP.  
8.6. Pharmacokinetics  
The PK analysis will be carried out according to Altasciences SOPs. P harmacokinetic  data 
handling and analysis will be further  detailed in the  SAP.  Pharmacokinetic analyses will be 
performed using the PK population.  
8.6.1.  Measurements Below the Lower Limit of Quantitation  
Concentration values below the lower limit of quantitation (LLOQ) associated with predose and 
postdose collection times will be replaced  with zero for the non -compartmental analyses (NCA).  
Concentration values below the LLOQ will be replaced with 0 for mean PK profile 
representations  as well as for descriptive statistic calculations.  
8.6.2.  Actual Time  
Analysis will be based on the actual samplin g times, except for predose samples, which will 
always be  reported as 0 , regardless of time deviations.  
The individual concentration/time profiles will be presented using actual sampling times whereas 
the mean concentration/time profiles and tables present ing summary statistics of 
concent ration -time series will be presented using nominal sampling times.  
Actual times will be listed in the report.  
8.6.3.  Noncompartmental  Analysis  (NCA)  
The following  configuration  for the NCA analysis (with Phoenix® WinNonlin® versio n 8, or 
higher) will be  used: 
Protocol No: AR26.3031.[ADDRESS_621184] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 59 of 84 
• Data:  Serial sampled data  
• Model /Dose options Type:  Plasma (200 -202) / Extravascular  
• AUC  Calculation  Method:  Linear  Trapezoidal  with Linear  Interpolation  
Reason for exclusion of AUC: In the case where less than [ADDRESS_621185] 
measurable observed concentration  
AUC0 -inf Area under the concentration time curve from time 0 to infinity  
8.6.4.  Pharmacokinetic Statistical Methodology  
[IP_ADDRESS].  Descriptive Statistics  
Descriptive statistics of the individual concentration data and derived parameters will be 
calculated with the build -in Phoenix® WinNonlin® platform and displayed with the same 
precision as received from the bioanalytical laboratory.  
Precision for individual values will be display as follows:  
• Cmax and AUC  will be displayed with the same precision as the raw PK concentration 
data 
• Parameters associated with time will be displayed with 2 decimal places  
Summary statistics will be displayed with the same precision as the individual values, with the 
exception of number of observations (N) and coefficient of variation (CV%) which will be  
presented with [ADDRESS_621186], respectively.  
Descriptive statistics will be calculated for concent rations at each individual time point and for all 
PK parameters. Individual concentrations, actual sampling times, and PK parameters obtained 
from the NCA will be summarized per treatment group using the following de scriptive statistics: 
N, minimum, arithmetic mean, geometric mean, median, maximum, standard deviation (SD), 
CV% . 
[IP_ADDRESS].  Statistical Analysis  
No formal statistical analysis of PK data will be perfor med.  
Protocol No: AR26.3031.[ADDRESS_621187] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 60 of 84 
8.7. Safety  
8.7.1.  Safety Endpoints  
For the treatment phase, safety endpoints will include a summary of the incidence of AEs, SAEs, 
as well as descriptive summary and statistics of the safety parameters (clinical laboratory values, 
vital signs [i.e.,  systolic and  diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], oral 
temperature, SpO 2], continuous SpO 2 monitoring, continuous EtCO 2 monitoring, ECGs, C -SSRS, 
and physical examination findings.  
8.7.2.  Safety Analysis  
The clinical laboratory tests and the measurements o f vital signs, continuous SpO 2 and EtCO 2 
monitoring, ECGs , C-SSRS and physical examination parameters will be used to perform the 
safety statistical analysis.  
8.7.3.  Safety Statistical Methodology  
[IP_ADDRESS].  Qualification Phase  
The Qualification Randomized population will be used to list all AEs occurring in the 
qualification phase. Qualification passes and failures will be listed separately.  
[IP_ADDRESS].  Treatment Phase  
Analysis of safety assessments will be performed using the Treatment Safety population. 
Assessment of  safety will be based on the incidence of AEs, AEs resulting in discontinuation, 
and SAEs by [CONTACT_3148]. AE summaries will be provided showing the number and percentage of 
subjects who experienced at least 1 TEAE during the treatment phase. TEAEs will also be 
tabulated by [CONTACT_483307]. Adverse events  will 
be presented by [CONTACT_49240] ( MedDRA, version 23.0 or higher). SAEs and 
AEs resulting in discontinuation will be summarized separately. All AE s will be listed by [CONTACT_483308].  
Laboratory data collected during the treatment phase will be summarized by [CONTACT_483309]. Descriptive statistics (n, mean, SD, minimum, median, and maximum) 
and the number of su bjects with laboratory test results below, within, and above normal ranges 
will be tabulated by [CONTACT_765]. Abnormal findings in laboratory data will be listed.  
Treatment phase vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697], SpO 2) and EtCO 2 will be 
analyzed as minimum, maximum, and final postdose values since the analyses of these extremes 
are more meaningful than analyses of individual timepoints. Vital signs will be summarized 
using descriptive statistics (n, mean, SD, minimum, median, and maximum).  Abnormal findings 
in vital signs data will be listed.  
12-Lead ECG data during the treatment phase (absolute values in heart rate and PR, QRS, QT, 
and QTcF intervals) will be summarized by [CONTACT_483310] (n, 
mean, SD, min imum, median, and maximum). Overall ECG interpretation will be summarized 
(normal; abnormal, non -clinically significant; and abnormal, clinically significant). Abnormal 
findings in ECG data will be listed.  
Protocol No: AR26.3031.[ADDRESS_621188] Number: ABO -P4-[ADDRESS_621189] 
visit scores  from the C -SSRS questionnaire will be listed. No summaries will be provided.  
8.8. Planned Interim Analyses  
No formal interim analyses will be performed.  
8.9. Determination of Sample Size  
The sample sizes are based on  data from Setnik et al.3030 which evaluated doses of 20 mg 
oxycodone and placebo; approximate means for oxycodone [ADDRESS_621190]  
For Drug Liking VAS E max VAS, the mean (SD) was 54.7 (3.9) for placebo, and 68 (15.6) for 
oxycodone [ADDRESS_621191] deviation (SD) of 15.[ADDRESS_621192] with a significance level of 
0.05, 34 completers would be needed for the comparison of oxycodone 15 mg vs. placebo, and 
13 completers would be needed for the comparison of oxyc odone 30 mg vs. placebo.  
Primary Comparison  
The primary comparison,  
Ho: μCOMBO  – μC ≥ δ 2 vs. H a: μCOMBO  – μC < δ 2 where δ 2 = 0.xx( μC ― μP), 
is written as a linear combination of three means as follows:  
Ho: 1.2μ C -0.2 μ P –μCOMBO  ≤ 0 versus H a: 1.2μ C -0.2 μ P –μCOMBO  > 0 
Using the information for oxycodone 15 mg for the estimate of 1.2μ C -0.2 μ P, the mean (SD) is 
82.66 (18.74).  The mean for oxycodone 15 mg was increased by 10% to approximate the mean 
for the combination drug. The mean (SD) for the comb ination drug is estimated to be 86 (15.6). 
Using a with a margin of 0, correlation of 0.[ADDRESS_621193] conservative estimate of 54 co mpleters for balanced sequences, drop -outs, and 
problematic subjects, approximately 66 subjects will be randomized into the treatment phase in 
order to ensure 54 completers.  
The SAS code for the sample size calculations are shown below.  
*Validation Test: O xycodone 15 mg;  
proc power; 
 pairedmeans test=diff  
 sides=u 
 nulldiff= 15 
 pairedmeans= 54.7|78 
Protocol No: AR26.3031.[ADDRESS_621194] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 62 of 84 
 pairedstddevs=( 3.9 15.6) 
 corr= 0 
 alpha= 0.05 
 power= 0.9 
 npairs= .; 
run; 
*Validation Test: Oxycodone 30 mg;  
proc power; 
 pairedmeans test=diff  
 sides=u 
 nulldiff= 15 
 pairedmeans= 54.7|84 
 pairedstddevs=( 3.9 15.6) 
 corr= 0 
 alpha= 0.05 
 power= 0.9 
 npairs= .; 
run; 
*Primary Comparison  
proc power; 
 pairedmeans test=diff  
 sides=u 
 alpha= 0.05 
 nulldiff= 0 
 pairedmeans= 82.66|86 
 pairedstddevs=( 18.74 15.6) 
 corr= 0.9 
 power= 0.9 
 npairs= .; 
run; 
Protocol No: AR26.3031.[ADDRESS_621195] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 63 of 84 
9. REFERENCES  
1. Bonnet U, Scherbaum N. How addictive are  gabapentin and  pregabalin ? A systematic 
review . Eur Neuropsychopharmacol. 2017 Dec;27(12):1185 -1215. doi: 
10.1016/j.euroneuro.2017.08.430. Epub [ADDRESS_621196] 5.  
2. Evoy KE, Covvey JR, Pe ckham AM, Ochs L, Hultgren KE. Reports of gabapentin and 
pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food and Drug 
Administration Adverse Events Reporting System (FAERS). Res Social Adm Pharm. 
2019; 953 -958. 
3. Draft Guidance for Ind ustry: Assessment of Abuse Potential of Drugs. U.S. Department 
of Health and Human Services. Food and Drug Administration. Center for Drug 
Evaluation and Research. January 2010 . 
4. Assessment of Abuse Potential of Drugs. U.S. Department of Health and Human 
Services. Food and Drug Administration. Center for Drug Evaluation and Research. 
January 2017.  
5. US Food and Drug Administration. Guidance for Industry: Abuse -Deterrent Opi[INVESTIGATOR_483264]. Guidance for Industry; April 2015.  
6. Balster  RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse 
liability assessment. Drug Alcohol Depend. 2003; 70([ADDRESS_621197]):S13 -40. 
7. Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse 
liability assessment in human s. Drug and Alcohol Depend. 2003; 70(3) Suppl: S41 -54.  
8. Levy -Cooperman N, Schoedel KA, Chakraborty B, Blum D, Cheng H. Abuse liability 
assessment of eslicarbazepi[INVESTIGATOR_483265]: a phase I randomized contro lled trial. Epi[INVESTIGATOR_41744]. 2016; 61:63 -71.  
9. Schoedel KA, Andreas JO, Doty P, Eckhardt K, Sellers EM. Randomized, double -blind, 
placebo - and active comparator -controlled crossover study evaluating the abuse potential 
of the antiepi[INVESTIGATOR_483266]. J Clin 
Psychopharmacol. 2017; 37(6):675 -683. 
10. Schoedel KA, Stockis A, Sellers EM. Human abuse potential of brivaracetam in healthy 
recreational central nervous system depressant users. Epi[INVESTIGATOR_41744]. 2018a; 78:194 -
201. 
11. Schoedel KA, Szeto I, Setnik B, et al. Abuse potential assessment of cannabidiol (CBD) 
in recreational polydrug users: A randomized, double -blind, controlled trial. Epi[INVESTIGATOR_297047]. 2018b; 88:162 -171. 
12. Horizant [Product Monograph] (October 2016).  
13. Schoedel KA, Sellers EM. Assessing abuse liability during drug development: changing 
standards and expectations. Clin Pharmaco Ther. 2008; 83(4):622 –626. 
doi:10.1038/sj.clpt.6100492.  
Protocol No: AR26.3031.[ADDRESS_621198] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 64 of 84 
14. Comer SD, Collins ED, MacArthur RB, Fischman  MW. Comparison of intravenous and 
intranasal heroin self -administration by [CONTACT_20901] -maintained humans. 
Psychopharmacology . 1999; 143: 327.338.  
15. Cashman, JN, Dolin SJ. Respi[INVESTIGATOR_483267]: evidence fro m published data.  British Journal of Anaesthesia.  2004; 
93 (2): 212 –23. 
16. Chen L, Tsong Y. Design and analysis for drug abuse potential studies: issues and 
strategies for implementing a crossover design. Drug Information J. 2007; 41:[ADDRESS_621199] drug and 
placebo in human abuse potential studies. J Biopharm Stat. 2013; 23(2):[ADDRESS_621200], Pocock SJ, Evans SJW, Altman DG. CONSORT (Consolidated 
Standards of Reporting Trials) Statement. Reporting of Noninferiority and Equivalence 
Randomized Trials -Extension of the CONSORT 2010 Statement. JAMA. 2012; 308(24): 
[ADDRESS_621201] statistics to non -normality 
and specification error in confirmatory factor analysis. Psychological Methods. 1996;  
1(1): p. 16 -29. 
20. Chen L. Principles and methods of statistical assessment of abuse -deterrent opi[INVESTIGATOR_2438]. Ther 
Innov Regul Sci. 2018; 52(1):7 -13. 
21. Mills C. Statistical Issues in Abuse -Deterrent Formulation (ADF) and Human Abuse 
Potential (HAP) Studies. CCALC, Abuse Potential Dialogue Session, [ADDRESS_621202]-2018.  
22. Evoy K, et al. Abuse and Misuse of Pregabalin and Gabap entin. Drugs. 2017; 77: 
403-426. 
23. Smith R, et al. Abuse and Diversion of Gabapentin Among  Nonmedical Prescription 
Opi[INVESTIGATOR_483268]. American Journa l of Psychiatry. 2015; 172(5): 
487-488. 
24. Willens T, et al. Prescription Medication Misuse Among Opi[INVESTIGATOR_483269]. The American Journal on Addictions. 2015; 24  :173-
177. 
25. Webster LR, et al. Randomized double -blind, placebo -controlled study of the abuse 
potential of different formulations of oral oxycodone. Pain Med. 2012, 13(6)  :790-801. 
26. Levy -Cooperman N, et al. Abuse Potential and Pharmacodynamic Characteristics of Oral 
and Intranasal Eluxadoline, a Mixed mu - and kappa - Opi[INVESTIGATOR_483270] -
Opi[INVESTIGATOR_483271]. The Journal of Pharmacology and Experimental Therapeutics.  
27. Ordóñez Gallego A, González Barón M, Espi[INVESTIGATOR_334652] E. Oxycodone: a 
pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):[ADDRESS_621203], Ling W. The Clinical O pi[INVESTIGATOR_2433] (COWS). J Psychoactive 
Drugs. 2003, 35 (2)  :253-9. 
Protocol No: AR26.3031.[ADDRESS_621204] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 65 of 84 
29. Pathak S, Vince B, Kelsh D, Setnik B, Nangia N, et al.  Abuse potential of samidorphan  : 
a phase [ADDRESS_621205] bo-controlled study. J Clin 
Pharmacol. 2019; 59(2)  : 218 -228. 
30. Setnik B, Roland CL, Pi[INVESTIGATOR_6852] G, Webster L. Measurement of Drug Liking in Abuse 
Potential Studies: A Comparison of Unipolar and Bipolar Visual Analog Scales. The 
Journal of Clinical Pharmacology . 2017 ; 57(2) 266 –274. 
31. Zacny JP, Gutierrez S. Characterizing the  subjective, psychomotor, and physiological 
effects of oral oxycodone in non -drug-abusing volunteers. Psychopharmacology . (2003) ; 
170:242 -254. 
32. Daniel, W. W. (1990). Applied Nonparametric Statistics, Second Edition, PWS -KENT 
Publishing Company.  
33. Chen L, Toll iver J, Calderon S., Chiapperino D. Improving the Design of Qualification 
Phase in Human Abuse Potential Studies. The College on Problems of Drug Dependence 
(CPDD) 81st Annual Scientific Meeting, June 15 -19, 2019.  
34. Chernik DA, Gillings D, Laine H, Hendler J , Silver JM, Davidson AB, Schwam EM, 
Siegel JL. Validity and reliability of the Observer's Assessment of Alertness/Sedation 
Scale: study with intravenous midazolam. J Clin Psychopharmacol. 1990 Aug;10(4):[ADDRESS_621206].  Physiologic, subjective, and behavioral 
effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and 
methylphenidate in man. Clin Pharmacol Ther . 1971;12(2):245 -258. 
36. Haertzen CA, Hill HE, Belleville RE. Development of the Addiction Research Cent er 
Inventory (ARCI): selection of items that are sensitive to the effects of various drugs. 
Psychopharmacologia . 1963;70:155 -166. 
37. Haertzen CA. An Overview of the Addiction Research Center Inventory (ARCI): An 
Appendix and Manual of Scales. Rockville, MD: N ational Institute on Drug Abuse; 1974.  
38. Linko K, Paloheimoi M. Inspi[INVESTIGATOR_483272] -tidal oxygen content difference: a sensitive 
indicator of hypoventilation. Crit Care Med . 1989;17(4):345 -348. 
39. Jabre P, Jacob L, Auger H, et al. Capnography monitoring in nonintub ated patients with 
respi[INVESTIGATOR_1506]. Am J Emerg Med . 2009;27(9):1056 -1059.  
40. Manifold CA, David N, Villers LC, Wampler DA. Capnography for the non -intubated 
patient in the emergency setting. J Emerg Med . 2013;45(4):626 -632. 
41. Waugh JB, Epps CA, Khodneva YA. Capnography enhances surveillance of respi[INVESTIGATOR_483273]: a meta -analysis. J Clin Anesth . 2011;23(3):[ADDRESS_621207] J . 
2012;9:13.  
Protocol No: AR26.3031.[ADDRESS_621208] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 66 of 84 
10. APPENDIX 1: ETHICS  
10.1. Institutional Review Board  
This protocol and the informed consent form ( ICF) will be submitted to an institutional review 
board ( IRB) prior to initiation  of the study and the study will not start until the bo ard has 
approved the documents. Notification of the b oard’s approval will be appended to the final 
report.  
10.2. Ethical Conduct of the Study  
This study will be conducted in compliance with the study protoco l, the ethical principles that 
have their origins in the Declaration of Hel sinki, the International Council for Harmonisation 
(ICH) Guideline E6 for Good Clinical Practice ( GCP ), the Food and Drug Administration ( FDA ) 
GCP Code of Federal Regulations (CFR) Title 21 (part 56), the European regulation EU 
536/2014 , and the Tri -Council Policy Statement (Canada) . 
10.3. Subject  Information and Consent  
Before screening activities commence, each subject will be given a copy of the  ICF to read, as 
well as a full explanation of the purpose of the study, the procedures to be carried out, and the 
potential adverse events ( AEs). Once this essential information is pr ovided to the subject and an 
investigator  or delegate  has the conviction the subject understands the implications of 
participating in the study, and if the subject chooses to continue the screening  process , they will 
be requested to sign and date a properly executed ICF prior to enrollment . Subjects will be 
assured they may withdraw from the study at any time without jeopardizing their medical care or 
future study participation (for which they  may qualify).  
Subjects will be given a signed copy of the ICF. If an amended or revised ICF is introduced 
during the study, each subject’s further consent must b e obtained.  
10.4. Subject Confidentiality  
Investigators and the sponsor will preserve the confidentiality of all subjects taking part in the 
study, in accordance wi th GCP and local regulations. Subjects shall be identified by a unique 
subject identifier on all study documents provided to the sponsor. In compliance with f ederal 
regulations/ICH GCP Guidelines, it is required an investigator and institution permit authorized 
representatives of the company, of the regulatory agency(s), and IRB access to review the 
subject’s original medical records for verification of study -related procedures and data. An 
investigator is obligated to inform the subject that his/her study -related records will be reviewed 
by [CONTACT_31714] -named  representatives without violating the subject’s confidentiality.  
Protocol No: AR26.3031.[ADDRESS_621209] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 67 of 84 
11. APPENDIX 2: DATA COLLECTION, RETENTION, A ND MONITORING  
11.1. Case Report Forms  
The data required by [CONTACT_483311] 2 ways. Source Documents are used in the clinic 
as recording devices during procedures The data is transcribed from source into an electronic 
data capture software (Medrio ) and stored in the secure database for each subject included in a 
clinical  trial (i.e., subjects randomized to the qualification phase which includes qualification 
failures, and subjects randomized to the treatment phase).  Pharmacodynamic/VAS data is 
electron ic.  
Data assembled outside the clinic source (i.e. , clinical laboratory data, pharmacokinetic [ PK] 
concentration data , and pharmacodynamics [ PD] measures [e.g., visual analog scale ( VAS ) 
scores] ), will be received from a specified external vendo r via an e lectronic data file. The file 
received encrypted (or posted to a secure File Transfer Protocol) and is stored in a secure folder 
on a server. The electronic data file(s)  are independent of the Medrio  electronic data c apture 
(EDC) data during the conduct of  the study.  
The Medrio  EDC cleaned data will be reviewed, approved an d electronically signed by [CONTACT_483312] i nvestigator or delegate. The Medrio  EDC data will be output in a case report form 
(CRF ) format. The external data files will be output in SAS® datasets . At review cycles, tables, 
figures and listings will be provided in rtf format. All data will be included with the final report 
provided to the sponsor.  
11.2. Data Management and Processing  
Data M anagement develops documentation to define activities performed during the data 
management conduct of the study trial . Medrio  EDC system is the tool used to conduct all data 
cleaning activities, monitoring activities and review/approval activities for clini c collected data 
and procedure data. The external data files are reconciled (to compare the external vendor data 
and Medrio  EDC sample collection data). Data Management activities are performed in 
accordance with the Data Management standard operating proc edures ( SOPs ). 
In addition to the cleaning activities, data entered in Medrio  EDC will be checked for accuracy 
through quality control ( QC) assessments. When the database data is declared to be complete and 
accurate : the database will be locked, and user a ccess removed.  
11.3. Quality Control and Quality Assurance  
Designated personnel from the quality assurance unit(s) of the clinical, PK , PD, and statistical 
facilities will be responsible for maintaining quality assurance ( QA) systems to ensure that the 
trial is conducted and that clinical/PK/ PD/statistical data is generated, documented and reported 
in compliance with the protocol and the integrated addendum to International Conference on 
Harmonisation ( ICH) E6: Guideline for Good Clinical Practice E6 (R2).  
Design ated personnel from each corresponding operation unit ( e.g., clinical, PK, PD, and 
statistical facilities) will be responsible to maintain and assure the QC of all data generated and 
documented in compliance with the protocol.  
All parts of the bioanalytica l phase of the study and all its documentation will be subject to 
inspection by [CONTACT_113144], 
Protocol No: AR26.3031.[ADDRESS_621210] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 68 of 84 
documented and reported in compliance with the protocol and applicable requirements as 
outlined  in the Food and Drug Administration ( FDA ) and Organisation for Economic 
Co-operation and Development ( OECD ) Principles of Good Laboratory Practice (GLP) . 
11.4. Record Retention  
All essential documents and records will be maintained by [CONTACT_113145], 
and for the period specified in the applicable regulatory requirement(s) (FDA Code of Federal 
Regulations [ CFR ] 312.57 (C)).  
11.5. Monitoring of the Study  
The sponsor  or its representative may monitor the study in order to maintain current and personal 
knowledge of the study through review of the records, comparison with source documents, 
observation and discussion of the conduct and progress of the study. The clinical  site will permit 
trial-related monitoring, audits, institutional review board (IRB)/independent ethics committee 
(IEC) review, and regulatory inspection(s) by [CONTACT_20618]/documents  
and read -only access to the EDC . 
Protocol No: AR26.3031.[ADDRESS_621211] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 69 of 84 
12. APPENDIX 3: ADMINISTRATIVE PROCEDURES  
12.1. Liabilities  
It is the sponsor’s responsibility to guarantee sufficient insurance coverage should any serious 
events or deaths result , either directly or indirectly, from the execution of the present protocol.  
12.2. Adherence to Protocol  
Excluding an emergency situation in which proper treatment is required for the protection, safety 
and well -being of the study subjects, the study will be conducted as described in the approved 
protocol and performed according to International Conf erence on Harmonisation ( ICH)/Good 
Clinical Practice ( GCP ) and the applicable regulatory requirements. Any deviation from the 
protocol will be recorded and explained.  
If amendments to the protocol and/or amendments or revisions to the informed consent form  
(ICF) are required, the modifications will be documented and submitted to an institutional review 
board ( IRB) for approval.  
12.3. Statement of Investigator  
The Food and Drug Administration ( FDA ) Form 1572 , Statement of Investigator [Title 21, CFR 
Part 312], will be signed by [CONTACT_54421] I nvestigator  (PI), and will be kept on file.  
12.4. Delegation of Investigator Duties  
In the context of this protocol, the term ‘an investigator’ includes the Principal Investig ator and 
any sub -investigator.  
An investigator will ensure all personnel involved in the trial are adequately qualified and 
informed about the protocol, any amendments to the protocol, the study treatments, and their 
trial-related duties and functions.  
An investigator will maintain a list of sub -investigator(s) and other appropriately qualified 
persons to whom he/she delegates significant trial -related duties.  
Should an investigator delegate the supervision of the study drug administration to a designated 
person, this individual must have the appropriate professional -legal qualifications and 
certifications. An investigator should also ensure key staff personnel have the appropriate 
medical qualifications to effectively conduct or supervise any potential resu scitation procedures.  
12.5. Premature Termination or Suspension  of a Study  
The sponsor or its representative may terminate the study at any time for scientific or corporate 
reasons.  
If the trial is prematurely terminated or suspended for any reason, the clinical  site or an 
investigator (or delegate ) should promptly inform the trial subjects, should assure appropriate 
therapy and follow -up for the subjects and should inform the regulatory authority(ies) when 
required.  
Protocol No: AR26.3031.[ADDRESS_621212] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 70 of 84 
13. APPENDIX 4: PROTOCOL  REVIEW AND  APPROVAL S 
 
TITLE: A Randomized, Double -Blind, Active - and Placebo -Controlled, 6-Way Crossover Study 
to Evaluate the Abuse Potential of Orally Administered Gabapentin Enacarbil Immediate 
Release Capsules Taken Alone and in Combination with Oxycodone in Healthy, Nondepend ent, 
Recreational Opi[INVESTIGATOR_305114]  
 
I have carefully read this study protocol and agree it contains all necessary information required 
to conduct this study. I agree to conduct the study according to this protocol and in accordance 
with Good Clinical Practice ( GCP ) and the applicable regulatory requirements.  
___________________________  ____________________  
Debra Kelsh , MD  Date (yyyy/mm/dd)  
Principal  Investigator  
[INVESTIGATOR_483274]. 
 
Protocol No: AR26.3031.[ADDRESS_621213] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 71 of 84 
TITLE:  A Randomized, Double -Blind, Active - and Placebo -Controlled, 6-Way Crossover Study 
to Evaluate the Abuse Potential of Orally Administered Gabapentin Enacarbil Immediate 
Release Capsules Taken Alone and  in Combination with Oxycodone in Healthy, Nondependent, 
Recreational Opi[INVESTIGATOR_483275], I am aware of, and agree to comply with, all of the procedures 
contained within this protocol.  
_____________________________  ____________________  
Steven D. Caras, MD, PhD   Date (yyyy/mm/dd)  
Vice President Clinical Development  
Arbor Pharmaceuticals, LLC  
Protocol No: AR26.3031.[ADDRESS_621214] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 72 of 84 
14. APPENDIX 5: LIST OF ABBREVIATIONS  
ACLS  Advanced cardiac life support  
ADE  Adverse drug event  
AE Adverse event  
Ab Antigen/antibody  
ALT  Alanine aminotransferase  
ARCI  Addiction Research Center Inventory  
AST  Aspartate aminotransferase  
AUC 0-T Area under the concentration -time curve from [ADDRESS_621215]  
CFR  Code of Federal Regulations  
cGMP  Current Good Manufacturing Practice  
CI Confidence interval  
Cmax Maximum concentration  
CNS  Central nervous system  
COWS  Clinical Opi[INVESTIGATOR_483276]  
C-SSRS  Columbia Suicide Severity Rating Scale  
CV%  Coefficient of variation  
DRESS  Drug rash with eosinophilia and systemic symptoms  
DSM -IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition  
ECG  Electrocardiogram  
EDC  Electronic data capture  
Emax Maximum (peak) effect  
Emin Minimum effect  
ER Extended -release  
ET Early termination  
Protocol No: AR26.3031.[ADDRESS_621216] Number: ABO -P4-[ADDRESS_621217]  
IU International unit  
IUD Intrauterine device  
i.v. Intravenous  
kg Kilogram  
LLOQ  Lower limit of quantitation  
MBG  Morphine -Benzedrine Group  
MCV  Mean corpuscular volume  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
MOAA/S  Modified Observer’s Assessment of Alertness/Sedation  
N Number of observations  
NCA  Noncompartmental analysis  
NCS  Not clinically significant  
OECD  Organization for Economic Co-operation and Development  
OTC  Over -the-counter  
Protocol No: AR26.3031.[ADDRESS_621218] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 74 of 84 
PCAG  Pentobarbital –Chlorpromazine –Alcohol Group  
PD Pharmacodynamic  
pH The logarithm, on the base 10, of the reciprocal of the hydrogen ion 
concentration  
PHN  Postherpetic neuralgia  
PI [INVESTIGATOR_483277]’s formula  
RLS Restless legs syndrome  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAR  Suspected adverse reaction  
SD Standard deviation  
SOC  System organ class  
SOP Standard operating procedure  
SpO2  Oxygen saturation  
TA_AUE  Time -averaged area under the effect -time curve  
TEAE  Treatment -emergent adverse event  
TE max Time of maximum (peak) effect  
TE min Time of minimum effect  
THC  Tetrahydrocannabinol  
Tlast Last measured observable concentration  
Tmax Time of maximum concentration  
TQTc  Thorough corrected QT  
US [LOCATION_002]  
USPI  [INVESTIGATOR_483278] -DDE  World Health Organization Drug Dictionary -Enhanced  
Protocol No: AR26.3031.[ADDRESS_621219] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 75 of 84 
15. APPENDIX 6: CLINICAL LABORATORY EVALUATIONS  
Clinical Laboratory Test  Panel  Description  
General biochemistry:  Sodium, potassium, chloride, glucose, blood urea nitrogen (BUN), creatinine , bilirubin total, alkaline 
phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and albumin  
Endocrinology:  Follicle stimulating hormone  (FSH; for postmenopausal female subjects)  
Hematology:  White cell count with differential (a bsolute values of neutrophil, lymphocyte, monocyte, eosinophil, and 
basophil), red cell count, hemoglobin, hematocrit, mean corpuscular volume (MCV), and platelet count  
Serology1: Human immunodeficiency virus (HIV) antigen/antibody ( Ag/Ab ) Combo, hepatitis B (HBsAg) and 
hepatitis  C (HCV)   
Urinalysis : Color, clarity, specific gravity, pH, leukocyte, protein, glucose, ketones, bilirubin, blood, nitrite, 
urobilinogen. Microscopic examination will only be performed if the dipstick test is outs ide of the 
reference range for leukocyte, blood, nitrite or protein  
Urine drug screen:  Alcohol, a mphetamines, barbiturates, cannabinoids, cocaine, opi[INVESTIGATOR_858] , benzodiazepi[INVESTIGATOR_1651],  and 
phencyclidine  
Urine OR serum pregnancy test:  To be performed for all female s ubjects  
 
1 Screening visit only.  
Protocol No: AR26.3031.[ADDRESS_621220] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 76 of 84 
16. APPENDIX 7: COLUMBIA -SUICIDE SEVERITY RATING SCALE (C -SSRS)  –
BASELINE/ SCREENING VERSION  
Protocol No: AR26.3031.[ADDRESS_621221] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 77 of 84 

Protocol No: AR26.3031.[ADDRESS_621222] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 78 of 84 
 

Protocol No: AR26.3031.[ADDRESS_621223] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 79 of 84 
17. APPENDIX 8 : COLUMBIA -SUICIDE SEVERITY RATING SCALE (C -SSRS) –SINCE 
LAST VISIT VERSION  
Protocol No: AR26.3031.[ADDRESS_621224] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 80 of 84 

Protocol No: AR26.3031.[ADDRESS_621225] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 81 of 84 
 

Protocol No: AR26.3031.[ADDRESS_621226] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 82 of 84 
18. APPENDIX 9: ADDICTION RESEARCH CENTER INVENTORY (ARCI) MORPHINE -
BENZEDRINE GROUP (MBG) SCALE  
Instructions:  Answer each question as to how you are feeling at this moment.  
One point is given for every “true” answer to the following : 
1. I would be happy all the time if I felt as I feel now  - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
2. I am in the mood to talk about the feeling I have - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
3. I am full of energy - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -   True □ 
 False □  
4. I would be happy all the time if I felt as I do now - - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
5. Things around me seem more pleasing than usual - - - - - - - - - - - - - - - - - - - -   True □ 
 False □  
6. I feel less discouraged than usual - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
7. I fear that I will lose the contentment that I have now - - - - - - - - - - - - - - - - - -  True □ 
 False □  
8. I feel as if something pleasant just happened to me - - - - - - - - - - - - - - - - - - -   True □ 
 False □  
9. Today I say things in the easiest possible way - - - - - - - - - - - - - - - - - - - - - - - -   True □ 
 False □  
10. I feel so good that I know other people can tell it - - - - - - - - - - - - - - - - - - - - -   True □ 
 False □  
11. I feel mo re clear -headed than dreamy - - - - - - - - - - - - - - - - - - - - - - - - - - - - -   True □ 
 False □  
12. I can completely appreciate what others are saying when I am in this mood - -  True □ 
 False □  
13. I feel as if I would be more popular with people today - - - - - - - - - - - - - - - - -   True □ 
 False □  
14. I feel a very pleasant emptiness - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -   True □ 
 False □  
15. I feel in complete harmony with the world and those about me - - - - - - - - - - -  True  □ 
 False □  
16. I have a pleasant feeling in my stomach - - - - - - - - - - - - - - - - - - - - - - - - - - - -   True □ 
 False □  
17. I feel high - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
 
Protocol No: AR26.3031.[ADDRESS_621227] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 83 of 84 
19. APPENDIX 10: ADDICTION RESEARCH CENTER INVENTORY (ARCI) 
PENTOBARBITAL -CHLORPROMAZINE -ALCOHOL GROUP (PCAG) SCALE  
1. I feel dizzy  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -- - - -  True □ 
 False □  
2. I feel like avoiding people, although I usually do not feel this way - - - - - - - - -  True □ 
 False □  
3. My speech is slurred - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
4. I have a feeling of just dra gging along rather than coasting - - - - - - - - - - - - - -  True □ 
 False □  
5. People might say that I am a little dull today - - - - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
6. My head feels heavy - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
7. I am not as active as usual - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
8. It seems harder than usual to move around - - - - - - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
9. I feel drowsy - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -- -  True □ 
 False □  
10. I am moody - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -- - - - - - -  True □ 
 False □  
11. I feel sluggish - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
12. I am full of energy - - - - - - - - - - - - - - - - - - - - - - - - -- - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
13. A thrill has gone through me one or more times since I started the test - - - - - -  True □ 
 False □  
14. I feel more excited than dreamy - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
15. I feel more clear -headed than dreamy - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  True □ 
 False □  
 
Protocol No: AR26.3031.[ADDRESS_621228] Number: ABO -P4-292 
 
Version 2.0, 13AUG2021  Page 84 of 84 
20. APPENDIX 11: CLINICAL OPI[INVESTIGATOR_483229] (COWS)  
 
